Sorrento Therapeutics (SRNE) 10-Q 8 Aug 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 02, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Trading Symbol	SRNE
Entity Registrant Name	Sorrento Therapeutics, Inc.
Entity Central Index Key	850,261
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		57,570,468

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 98,179	$ 39,038
Marketable securities	34,946	97,366
Grants and accounts receivables, net	867	903
Income tax receivable	1,715	1,715
Notes receivable	10,000	0
Prepaid expenses and other, net	556	1,996
Total current assets	146,263	141,018
Property and equipment, net	9,203	7,246
Intangibles, net	3,690	3,912
Goodwill	20,626	20,626
Investments in common stock	112,008	112,008
Equity method investments	59,090	58,119
Other, net	524	590
Total assets	351,404	343,519
Current liabilities:
Accounts payable	4,423	1,339
Accrued payroll and related	1,491	2,361
Current portion of deferred compensation	944	891
Accrued expenses	37,102	3,927
Acquisition consideration payable	12,000	12,000
Derivative liability	0	5,520
Current portion of debt	5,067	4,835
Total current liabilities	61,027	30,873
Long-term debt	1,801	4,394
Deferred compensation	12	12
Deferred tax liabilities	35,047	49,341
Deferred revenue	110,875	110,900
Deferred rent and other	7,414	7,061
Total liabilities	216,176	202,581
Commitments and contingencies
Equity:
Preferred stock, $0.0001 par value; 100,000,000 shares authorized and no shares issued or outstanding	0	0
Common stock, $0.0001 par value; 750,000,000 shares authorized and 65,448,566 and 37,771,459 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively	7	4
Additional paid-in capital	336,952	184,898
Accumulated other comprehensive income	25,454	73,579
Stock subscription receivable	(43,502)	0
Accumulated deficit	(176,668)	(113,329)
Total Sorrento Therapeutics, Inc. stockholders' equity	142,243	145,152
Noncontrolling interests	(7,015)	(4,214)
Total equity	135,228	140,938
Total liabilities and equity	$ 351,404	$ 343,519

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	65,448,566	37,771,459
Common stock, shares outstanding	65,448,566	37,771,459

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenues:
Grant	$ 328	$ 459	$ 757	$ 697
Sales and services	574	714	1,133	1,453
Total revenues	902	1,173	1,890	2,150
Operating costs and expenses:
Costs of revenues	295	314	654	823
Research and development	10,631	7,971	18,408	15,811
Acquired in-process research and development	32,000	0	45,000	0
General and administrative	4,220	3,072	8,715	5,291
Intangible amortization	111	349	222	935
Total costs and operating expenses	47,257	11,706	72,999	22,860
Loss from operations	(46,355)	(10,533)	(71,109)	(20,710)
Gain on expiration of derivative liability	0	0	5,520	0
Income (loss) on equity investments	470	0	(29)	0
Interest expense	(273)	(442)	(580)	(881)
Interest income	45	0	58	0
Income (loss) before income tax	(46,113)	(10,975)	(66,140)	(21,591)
Income tax benefit	0	(17)	0	(195)
Net loss	(46,113)	(10,958)	(66,140)	(21,396)
Net loss attributable to noncontrolling interests	(1,164)	0	(2,801)	0
Net loss attributable to Sorrento	$ (44,949)	$ (10,958)	$ (63,339)	$ (21,396)
Net loss per share - basic and diluted per share attributable to Sorrento	$ (0.97)	$ (0.30)	$ (1.50)	$ (0.59)
Weighted-average shares used during period - basic and diluted per share attributable to Sorrento	46,498	36,315	42,228	36,261

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net loss attributable to Sorrento	$ (44,949)	$ (10,958)	$ (63,339)	$ (21,396)
Other comprehensive income:
Unrealized loss on marketable securities, net of tax	(11,236)	0	(48,125)	0
Total other comprehensive income	(11,236)	0	(48,125)	0
Comprehensive income (loss) attributable to Sorrento	(56,185)	(10,958)	(111,464)	(21,396)
Comprehensive income (loss) attributable to noncontrolling interests	0	0	0	0
Comprehensive income (loss)	$ (56,185)	$ (10,958)	$ (111,464)	$ (21,396)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Operating activities
Net loss	$ (66,140)	$ (21,396)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,101	1,427
Non-cash interest expense	123	202
Stock-based compensation	2,391	2,830
Acquired in-process research and development	30,000	0
Provision for doubtful accounts	29	4
Gain on expiration of derivative liability	(5,520)	0
Loss on equity investments	29	0
Deferred tax provision	0	(199)
Changes in operating assets and liabilities:
Grants and other receivables	7	(170)
Prepaid expenses and other	478	(242)
Accounts payable	3,084	321
Deferred revenue	(25)	0
Accrued expenses and other liabilities	2,081	9,671
Net cash used for operating activities	(32,362)	(7,552)
Investing activities
Purchases of property and equipment	(2,230)	(500)
Investments in common stock	0	(11,500)
Net cash used in investing activities	(2,230)	(12,000)
Financing activities
Net principal payments under loan and security agreement	(2,431)	(758)
Net payments of deferred compensation	0	(1,000)
Proceeds from issuance of common stock, net of issuance costs	95,751	0
Proceeds from exercise of stock options	413	1,107
Net cash provided by (used in) financing activities	93,733	(651)
Net change in cash and cash equivalents	59,141	(20,203)
Cash and cash equivalents at beginning of period	39,038	71,902
Cash and cash equivalents at end of period	98,179	51,699
Cash paid during the period for:
Income taxes	1	0
Interest paid	580	0
Supplemental disclosures of non-cash investing and financing activities:
Change in unrealized gains or (losses) on marketable securities	(62,420)	0
Stock subscription receivable and note receivable issued	53,502
Property and equipment costs incurred but not paid	$ 578	$ 497

Nature of Operations and Busine

Nature of Operations and Business Activities	6 Months Ended
	Jun. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Operations and Business Activities	1. Nature of Operations and Business Activities Nature of Operations and Basis of Presentation Sorrento Therapeutics, Inc. (NASDAQ: SRNE), together with its subsidiaries (collectively, the “Company”) is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs worldwide. The Company’s primary therapeutic focus is oncology, including the treatment of chronic cancer pain, but is also developing therapeutic products for other indications, including immunology and infectious diseases. The Company currently has multiple clinical development programs underway: (i) Chimeric Antigen Receptor-T Cell (“CAR-T”) programs for solid tumors, (ii) resiniferatoxin, or RTX, a non-opiate, ultra-potent and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease, and (iii) its clinical development programs for its biosimilar/biobetter antibodies. The Company’s pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including its biosimilars/biobetters, its fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its proprietary G-MAB ® ® Through June 30, 2016, the Company had devoted substantially all of its efforts to research and product development, raising capital and building infrastructure, and had not realized revenues from its planned principal operations. The accompanying interim consolidated financial statements have been prepared by the Company, without audit, in accordance with the instructions to Form 10-Q and, therefore, do not necessarily include all information and footnotes necessary for a fair statement of its financial position, results of operations and cash flows in accordance with United States generally accepted accounting principles (GAAP). The accompanying consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries and those of a variable interest entity where the Company is the primary beneficiary. For consolidated entities where the Company owns or are exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Sorrento Therapeutics, Inc. Hong Kong Limited had no operating activity through June 2016. All intercompany balances and transactions have been eliminated in consolidation. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way the Company accounts for its existing collaborative relationships and other arrangements. The Company continuously assesses whether it is the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the Company consolidating or deconsolidating one or more of its collaborators or partners. The balance sheet at December 31, 2015 is derived from the audited consolidated financial statements at that date which are not presented herein. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of financial position, results of operations and cash flows. These consolidated financial statements should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015. Operating results for interim periods are not expected to be indicative of operating results for the Company’s 2016 fiscal year. Liquidity The Company anticipates that it will continue to incur net losses in the foreseeable future as it (i) advances clinical stage product candidates such as biosimilar/biobetter antibodies, CAR-T programs and RTX in the clinic and potentially pursues other development, (ii) continues to identify a number of potential mAb and ADC drug candidates and further advances various preclinical and development activities, (iii) advances its product candidates into the clinic, (iv) invests in additional joint ventures or third party collaboration or acquisition agreements, and (v) expands corporate infrastructure, including the costs associated with being a NASDAQ listed public company. Based on currently available resources, the Company believes it has the ability to meet all obligations due over the course of the next twelve months. On April 3, 2016, the Company entered into a Securities Purchase Agreement (the “ABG Purchase Agreement”) with ABG SRNE Limited and Ally Bridge LB Healthcare Master Fund Limited (collectively, “Ally Bridge”), pursuant to which, among other things, the Company agreed to issue and sell to Ally Bridge and other purchasers that may be designated by Ally Bridge (collectively, the “ABG Purchasers”), in a private placement transaction (the “ABG Private Placement”), up to $50.0 million in shares of common stock of the Company (“Common Stock”) and warrants to purchase shares of Common Stock. Upon the closing of the ABG Private Placement, the Company will issue to each ABG Purchaser (1) such number of shares (the “ABG Shares”) of Common Stock as is equal to the amount of such ABG Purchaser’s investment divided by $5.55, provided that Under the terms of the ABG Purchase Agreement, the Company is obligated to prepare and file with the Securities and Exchange Commission (the “SEC”), within 30 days of the closing date of the ABG Private Placement, a registration statement to register for resale the ABG Shares and the shares of Common Stock issuable upon exercise of each ABG Warrant (the “ABG Warrant Shares”), and may be required to effect certain registrations to register for resale the ABG Shares and the ABG Warrant Shares in connection with certain “piggy-back” registration rights granted to the ABG Purchasers. On April 3, 2016, the Company also entered into a Securities Purchase Agreement (collectively, the “Additional Purchase Agreements”) with each of Beijing Shijilongxin Investment Co., Ltd. ( “Beijing Shijilongxin”), FREJOY Investment Management Co., Ltd. (“Frejoy”) and Yuhan Corporation (“Yuhan”), pursuant to which, among other things, the Company agreed to issue and sell, in separate private placement transactions: (1) to Beijing Shijilongxin, 8,108,108 shares of Common Stock, and a warrant to purchase 1,176,471 shares of Common Stock, for an aggregate purchase price of $45.0 million; (2) to Frejoy, 8,108,108 shares of Common Stock, and a warrant to purchase 1,176,471 shares of Common Stock, for an aggregate purchase price of $45.0 million; and (3) to Yuhan, 1,801,802 shares of Common Stock, and a warrant to purchase 235,294 shares of Common Stock, for an aggregate purchase price of $10.0 million. The warrants to be issued pursuant to each of the Additional Purchase Agreements (collectively, the “Additional Warrants” and, together with each ABG Warrant, the “Warrants”) will have an exercise price of $8.50 per share, will be immediately exercisable upon issuance, will have a term of three years and will be exercisable on a cash or cashless exercise basis. Under the terms of the Additional Purchase Agreements, each of Beijing Shijilongxin, Frejoy and Yuhan has the right to demand, at any time beginning six months after the closing of the transactions contemplated by the applicable Additional Purchase Agreement, that the Company prepare and file with the SEC a registration statement to register for resale such investor’s shares of Common Stock purchased pursuant to the applicable Additional Purchase Agreement and the shares of Common Stock issuable upon exercise of such investor’s Additional Warrant. In addition, the Company may be required to effect certain registrations to register for resale such shares in connection with certain “piggy-back” registration rights granted to Beijing Shijilongxin, Frejoy and Yuhan. On May 2, 2016 the Company announced that it closed its previously announced private placement financing of common stock and warrants with Yuhan Corporation for gross proceeds of $10.0 million. Yuhan purchased 1,801,802 shares of common stock at $5.55 per share and a warrant to purchase 235,294 shares of common stock. The warrant is exercisable for three years at an exercise price of $8.50 per share. On June 8, 2016 the Company announced that is closed on the remainder of the $150.0 million financing. Ally Bridge Group ("ABG"), a global healthcare-focused investment group based in Hong Kong, led the financing and, together with Beijing Shijilongxin Investment Co., Ltd. ("Beijing Shijilongxin"), and FREJOY Investment Management Co., Ltd. ("Frejoy") collectively purchased 25,225,221 shares of common stock at $5.55 per share, and warrants to purchase 5,055,642 shares of common stock for total consideration of $140.0 million. The Company plans to continue to fund its operating losses and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. On July 11, 2016 the Company announced a license and collaboration agreement with Les Laboratoires Servier, SAS, a corporation incorporated under the laws of France, and Institut de Recherches Internationales Servier, a company duly organized and existing under the laws of France (individually and collectively, “Servier”) for the development, manufacture and commercialization of products using Sorrento's fully human immuno-oncology anti-PD-1 monoclonal antibody (mAb) STI-A1110. Pursuant to the financial terms of that agreement the Company received a non-refundable up-front payment of $27.4 million in July of 2016. The Company filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (“SEC”), which was declared effective by the SEC in July 2013 (the “2013 Shelf Registration Statement”). The 2013 Shelf Registration Statement provides the Company the ability to offer up to $100.0 million of securities, including equity and other securities as described in the registration statement. After the May 2014 underwritten offering the Company has the ability to offer up to $36.6 million of additional securities under the 2013 Shelf Registration Statement. In November 2014, the Company filed a universal shelf registration statement on Form S-3 with the SEC, which was declared effective by the SEC in December 2014 (the “2014 Shelf Registration Statement”). The 2014 Shelf Registration Statement provides the Company with the ability to offer up to $250.0 million of securities, including equity and other securities as described in the registration statement. Included in the 2014 Shelf Registration Statement is a sales agreement prospectus covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $50.0 million of the Company’s common stock that may be issued and sold under a sales agreement with MLV & Co. LLC (the “ATM Facility”). Subsequent to June 30, 2016, the Company completed a letter agreement with the Chan Soon-Shiong Family Foundation (“Foundation”) and Cambridge Equities, LP (“Cambridge”) (the “Letter Agreement”). Pursuant to the terms of the Letter Agreement, among other things, (a) the Company agreed to sell to Foundation, and Foundation agreed to purchase from the Company, an aggregate of 5,618,326 shares of common stock of NantKwest, Inc. held by the Company, (b) Foundation agreed to sell to the Company, and the Company agreed to purchase all reported shares held by Foundation and Cambridge, an aggregate of 7,878,098 shares of common stock of the Company (“Common Stock”) held by Foundation and Cambridge, (c) Cambridge agreed to forfeit its right to purchase 500,000 shares of Common Stock issuable pursuant a warrant to purchase 1,724,138 shares of Common Stock held by Cambridge, and (d) the Company agreed to pay to Foundation an aggregate of approximately $15.6 million. The transactions contemplated under the Letter Agreement closed on July 7, 2016. Effective with the close of the transaction in July 2016, the Company will retire the 7,878,098 shares and has the ability to sell these shares for additional funds. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial covenants that may restrict the Company’s ability to operate its business.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Significant Accounting Policies	2. Significant Accounting Policies Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including those related to the valuation of warrants, stock-based compensation and the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. The Company has not experienced any losses on such accounts. Fair Value of Financial Instruments The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments: · Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments. · Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace. · Level 3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange. The carrying amounts of cash equivalents and marketable securities approximate their fair value based upon quoted market prices. Certain of our financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, accounts receivable and payable, and other financial instruments in current assets or current liabilities. Marketable Securities Marketable securities are designated as available-for-sale securities and are accounted for at fair value. Marketable securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Marketable securities that are readily available for use in current operations are classified as short-term available-for-sale securities and are reported as a component of current assets in the accompanying consolidated balance sheets. Marketable securities that are not considered available for use in current operations are classified as long-term available-for-sale securities and are reported as a component of long-term assets in the accompanying consolidated balance sheets. Securities that are classified as available-for-sale are carried at fair value, with temporary unrealized gains and losses reported as a component of stockholders' equity until their disposition. The cost of securities sold is based on the specific identification method. All of the Company’s marketable securities are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. For the three and six months ended June 30, 2016, no other-than-temporary impairment charges were recorded. Grants and Accounts Receivable Grants receivable at June 30, 2016 and December 31, 2015 represent amounts due under several federal contracts with the National Institute of Allergy and Infectious Diseases, or NIAID, a division of the National Institutes of Health, or NIH, collectively, the NIH Grants. The Company considers the grants receivable to be fully collectible; accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations. Accounts receivable at June 30, 2016 and December 31, 2015 consists of trade receivables from sales and services provided to certain customers, which are generally unsecured and due within 30 days. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for doubtful accounts within grants and accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for doubtful accounts. As of June 30, 2016 and December 31, 2015, the allowance for doubtful accounts was $29,000 and $4,000, respectively. Property and Equipment Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally three to five years. Leasehold improvements are amortized over the lesser of the life of the lease or the life of the asset. Repairs and maintenance are charged to expense as incurred. Acquisitions and Intangibles The Company has engaged in business combination activity. The accounting for business combinations requires management to make judgments and estimates of the fair value of assets acquired, including the identification and valuation of intangible assets, as well as liabilities assumed. Such judgments and estimates directly impact the amount of goodwill recognized in connection with each acquisition, as goodwill presents the excess of the purchase price of an acquired business over the fair value of its net tangible and identifiable intangible assets. Goodwill and Other Long-Lived Assets Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment in the fourth quarter of 2015, noting no impairment. There have not been any triggering events through June 30, 2016. The Company evaluates its long-lived assets with definite lives, such as property and equipment, acquired technology, customer relationships, patent and license rights, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of non-generic and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of the life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets’ book value to future net undiscounted cash flows that the assets are expected to generate. There have not been any impairment losses of long-lived assets through June 30, 2016. Derivative Liability Derivative liabilities are recorded on the consolidated balance sheets at fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. The Company estimates the fair value of derivative liabilities using the Black-Scholes option pricing model. Investments in Other Entities The Company holds a portfolio of investments in equity securities that are accounted for under either the equity method or cost method. Investments in entities over which the Company has significant influence but not a controlling interest are accounted for using the equity method, with the Company’s share of earnings or losses reported in other income (expense), net. The Company’s cost method investments are included in investments in common stock on the consolidated balance sheets. The Company’s equity method investments are included in equity method investments on the consolidated balance sheets. All investments are reviewed on a regular basis for possible impairment. If an investment's fair value is determined to be less than its net carrying value and the decline is determined to be other-than-temporary, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an other-than-temporary decline in value has occurred include: market value or exit price of the investment based on either market-quoted prices or future rounds of financing by the investee; length of time that the market value was below its cost basis; financial condition and business prospects of the investee; the Company’s intent and ability to retain the investment for a sufficient period of time to allow for recovery in market value of the investment; issues that raise concerns about the investee's ability to continue as a going concern; any other information that we may be aware of related to the investment. The Company does not report the fair value of its equity investments in non-publicly traded companies because it is not practical to do so. Research and Development Costs and Collaborations All research and development costs are charged to expense as incurred. Such costs primarily consist of lab supplies, contract services, stock-based compensation expense, salaries and related benefits. Acquired In-Process Research and Development Expense The Company has acquired and may continue to acquire the rights to develop and commercialize new drug candidates. The up-front payments to acquire a new drug compound, as well as future milestone license payments, are immediately expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. Income Taxes The provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740-10, Uncertainty in Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has uncertain tax positions. The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of June 30, 2016 and December 31, 2015, the Company maintained a full valuation allowance against its deferred tax assets, with the exception of an amount equal to its deferred tax liabilities, which can be expected to reverse over a definite life. Revenue Recognition The Company’s revenues are generated primarily from various NIH grant awards, and from the sale of customized reagents and the provision of contract development services. The revenue from the NIH grant awards is based upon subcontractor and internal costs incurred that are specifically covered by the grant, and where applicable, a facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs internal expenses that are related to the grant. Revenues from sales are generated from the sale of customized reagents which include industrial standard cytotoxins, linkers, and linker-toxins used for preparing ADCs. Contract development services include providing synthetic expertise to customer’s synthesis by delivering proprietary cytotoxins, linkers and linker-toxins and ADC service using industry standard toxin and antibodies provided by customers. Revenue is recognized when, (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the services have been rendered, (iii) the price is fixed or determinable, and (iv) collectability is reasonably assured. License fees for the licensing of product rights are recorded as deferred revenue upon receipt of cash and recognized as revenue on a straight-line basis over the license period. The Company is obligated to accept from customers the return of products sold that are damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the terms of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company has not experienced any sales returns. Stock-based Compensation The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is generally measured at the grant date, based on the calculated fair value of the award and an estimate of forfeitures, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant). The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options and restricted stock granted to non-employees is re-measured over the vesting period, and the resulting changes in fair value are recognized as expense in the period of the change in proportion to the services rendered to date. Net Earnings (Loss) per Share Basic net earnings (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted net earnings (loss) per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options or the exercise of outstanding warrants. The treasury stock method and if-converted method are used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net earnings (loss) per share when their effect is anti-dilutive. In periods where a net loss is presented, all potentially dilutive securities are anti-dilutive and are excluded from the computation of diluted net loss per share. Comprehensive Income (Loss ) Comprehensive income (loss) is comprised of net income (loss) and adjustments for the change in unrealized gains and losses on our investments in available-for-sale marketable securities, net of taxes. The Company displays comprehensive income (loss) and its components in its consolidated statements of comprehensive income (loss). Segment Information The Company is engaged primarily in the discovery and development of innovative therapies focused on oncology and the treatment of chronic cancer pain as well as immunology and infectious diseases based on its platform technologies. Accordingly, the Company has determined that it operates in one operating segment. Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). In April 2016, the FASB issued Accounting Standards Update No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. Revenue from Contracts with Customers (Topic 606), In May 2016, the FASB issued Accounting Standards Update No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients. Revenue from Contracts with Customers (Topic 606), In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements The Company measures the fair value of financial assets and liabilities based on authoritative guidance that defines fair value, establishes a framework consisting of three levels for measuring fair value, and requires disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Company’s marketable securities are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets. The Company’s derivative liability was classified within Level 3 of the fair value hierarchy because the value was calculated using significant judgment based on the Company’s own assumptions in the valuation of this liability. The following table presents the Company’s financial assets and liabilities that are measured at fair value on a recurring basis. (in thousands): Fair Value Measurements at June 30, 2016 Balance Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Marketable securities $ 34,946 $ 34,946 $ — $ — Total assets $ 34,946 $ 34,946 $ — $ — Fair Value Measurements at December 31, 2015 Balance Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Marketable securities $ 97,366 $ 97,366 $ — $ — Total assets $ 97,366 $ 97,366 $ — $ — Liabilities: Derivative liability $ 5,520 $ — $ — $ 5,520 Total liabilities $ 5,520 $ — $ — $ 5,520 The following table includes a summary of the derivative liability measured at fair value using significant unobservable inputs (Level 3) during the six months ended June 30, 2016 (in thousands): Derivative Liability Beginning balance at December 31, 2015 $ 5,520 Gain on expiration of derivative liability (5,520 ) Ending balance at June 30, 2016 $ —

Marketable Securities

Marketable Securities	6 Months Ended
	Jun. 30, 2016
Investments Debt And Equity Securities [Abstract]
Marketable Securities	4 . Marketable Securities Marketable securities consisted of the following as of June 30, 2016 (in thousands): June 30, 2016 Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Available-for-sale securities: NantKwest common shares $ 10,000 $ 87,366 $ (62,420 ) $ 34,946 On July 27, 2015, NantKwest, Inc., or NantKwest, completed its initial public offering (“IPO”). Prior to the IPO the Company’s investment in NantKwest was accounted for using the cost method and the total investment of $10.0 million was classified as part of investments in common stock on the Company’s consolidated balance sheets. The common shares were subject to restrictions in a lock-up agreement through December 27, 2015 as well as limitations under Rule 144 of the Securities Act of 1933. As these were short term restrictions, the Company did not apply a marketability discount. For the three and six months ended June 30, 2016, the Company recorded an unrealized loss of $11.2 million and $48.1 million, respectively, representing the difference between the $10.0 million cost basis and the estimated fair value net of tax of $0 as of June 30, 2016, as accumulated other comprehensive income in the stockholder's equity section of the Company’s consolidated balance sheet and as a change in unrealized gains and losses on marketable securities in the Company’s consolidated statements of comprehensive income (loss). The tax effect of $14.3 million on the unrealized gain on marketable securities as of December 31, 2015 was reversed during the three months ended March 31, 2016 due to the decrease in the value of the marketable securities as of March 31, 2016.

Notes Receivable

Notes Receivable	6 Months Ended
	Jun. 30, 2016
Receivables [Abstract]
Notes Receivables	5. Notes Receivable In June 2016, the Company closed its previously announced securities purchase agreements with certain investors. In addition to the cash received the Company received consideration in the form of secured promissory notes for 9,640,060 shares totaling $53.5 million (the Secured Notes). The Secured Notes accrue interest at 5% per annum, and all principal and interest is due and payable in December, 2016. The Secured Notes are collateralized by the assets of the investors. In July 2016, the Company received a partial payment with accrued interest from one investor totaling $10.0 million and the Company expects to receive the remaining $43.5 million prior to December 31, 2016. The $43.5 million in notes are reflected as a stock subscription receivable in the Company’s consolidated balance sheets.

Investments

Investments	6 Months Ended
	Jun. 30, 2016
Investments [Abstract]
Investment	6. Investments As of June 30, 2016 and December 31, 2015, the aggregate carrying amount of the Company’s cost-method investments in non-publicly traded companies was $112.0 million CARgenix I n August 2015, the Company and TNK Therapeutics, Inc. (“TNK”), its subsidiary entered into a Membership Interest Purchase Agreement (the “Membership Interest Purchase Agreement”) with CARgenix Holdings LLC (“CARgenix”) and the members of CARgenix (the “Members”) pursuant to which the Members sold all of their membership interests in CARgenix to TNK for: (1) a cash payment of $100.00, and (2) $6.0 million in shares of TNK Class A common stock, subject to adjustment in certain circumstances, to be issued to the Members upon a financing resulting in gross proceeds (individually or in the aggregate) to TNK of at least $50.0 million (a “Qualified Financing”). In accordance with the March 2016, Amendment No. 1, in the event a Qualified Financing does not occur by September 15, 2016 or TNK does not complete an initial public offering of shares of its capital stock by October 15, 2016, in lieu of receiving shares of TNK pursuant to the acquisition, the Members shall receive an aggregate of 309,917 shares of Company common stock, subject to adjustment in certain circumstances. The Membership Interest Purchase Agreement further provides that 20% of the shares of TNK or the Company’s, as applicable, issuable to the Members shall be held in escrow to secure certain post-closing adjustment and indemnification rights of TNK for a period of 12 months following the closing of the transaction. The aggregate purchase price of $6.0 million was recognized as acquired in-process research and development expense in the consolidated statement of operations during the three months ended September 30, 2015. The corresponding acquisition liability will remain until settlement. BDL In August 2015, the Company and TNK entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with BDL Products, Inc. (“BDL”) and the stockholders of BDL (“Stockholders”) pursuant to which the Stockholders sold all of their shares of capital stock in BDL to TNK for: (1) a cash payment of $100.00, and (2) $6.0 million in shares of TNK Class A common stock, subject to adjustment in certain circumstances, to be issued to the Stockholders upon a Qualified Financing. In accordance with the March 2016, Amendment No. 1, in the event a Qualified Financing does not occur by September 15, 2016 or TNK does not complete an initial public offering of shares of its capital stock by September 30, 2016, in lieu of receiving shares of TNK pursuant to the acquisition, the Stockholders shall receive an aggregate of 309,917 shares of Company common stock, subject to adjustment in certain circumstances. The Stock Purchase Agreement further provides that 20% of the shares of TNK or the Company’s, as applicable, issuable to the Stockholders shall be held in escrow to secure certain post-closing adjustment and indemnification rights of TNK for a period of 12 months following the closing of the transaction. The aggregate purchase price of $6.0 million was recognized as acquired in-process research and development expense in the consolidated statement of operations during the three months ended September 30, 2015. The corresponding acquisition liability will remain until settlement.

Equity Method Investments

Equity Method Investments	6 Months Ended
	Jun. 30, 2016
Equity Method Investments And Joint Ventures [Abstract]
Equity Method Investments	7 . Equity Method Investments NANTibody In April 2015, the Company and NantCell, Inc., or NantCell, a wholly-owned subsidiary of NantWorks, Inc., a private company owned by Dr. Patrick Soon-Shiong, an affiliate of the Company, established a new joint venture called Immunotherapy NANTibody, LLC, or NANTibody, as a stand-alone biotechnology company with $100.0 million initial joint funding. NantCell owns 60% of the equity interest of NANTibody and agreed to contribute $60.0 million to NANTibody. The Company owns 40% of NANTibody and in July 2015, the Company had NantPharma, LLC, or NantPharma, contribute its portion of the initial joint funding of $40.0 million to NANTibody from the proceeds of the sale of IgDraSol. NANTibody will focus on accelerating the development of multiple immuno-oncology monoclonal antibodies (mAbs) for the treatment of cancer, including but not limited to anti-PD-1, anti-PD-L1, anti-CTLA4 mAbs, and other immune-check point antibodies as well as antibody drug conjugates (ADCs) and bispecific antibodies. The Company is accounting for its interest in NANTibody as an equity method investment, due to the significant influence the Company has over the operations of NANTibody through its board representation and 40% voting interest. The Company’s investment in NANTibody is reported in equity method investments on the consolidated balance sheets and its share of NANTibody’s income or loss is recorded in income (loss) on equity investments on the consolidated statement of operations. The financial statements of NANTibody are not received sufficiently timely for the Company to record its portion of earnings or loss in the current financial statements and therefore the Company reports its portion of earnings or loss on a quarter lag. As of June 30, 2016, the carrying value of the Company’s investment in NANTibody was approximately $39.9 million. NANTibody recorded a total net income of $806,000 for the three months ended March 31, 2016 and a net loss of $964,000 for the three months ended December 31, 2015. The Company recorded a total net income of $322,000 for the three months ended June 30, 2016 and a loss of $63,000 for the six months ended June 30, 2016 from NANTibody in income (loss) on equity investments on the consolidated statement of operations. As of March 31, 2016, NANTibody had $100.4 million in current assets and $628,000 in current liabilities. NantStem In July 2015, the Company and NantBioScience, Inc., or NantBioScience, a wholly-owned subsidiary of NantWorks, established a new joint venture called NantCancerStemCell, LLC, or NantStem, as a stand-alone biotechnology company with $100.0 million initial joint funding. As initially organized, NantBioScience was obligated to make a $60.0 million cash contribution to NantStem for a 60% equity interest in NantStem, and the Company was obligated to make a $40.0 million cash contribution to NantStem for a 40% equity interest in NantStem. Fifty percent of these contributions were funded in July 2015 and the remaining amounts were to be made by no later than September 30, 2015. The Company had NantPharma contribute its portion of the initial joint funding of $20.0 million to NantStem from the proceeds of the sale of IgDraSol. The Company is accounting for its interest in NantStem as an equity method investment, due to the significant influence the Company has over the operations of NantStem through its board representation and 20% voting interest. The Company’s investment in NantStem is reported in equity method investments on the consolidated balance sheets and its share of NantStem’s income or loss is recorded in income (loss) on equity investments on the consolidated statement of operations. The financial statements of NantStem are not received sufficiently timely for the Company to record its portion of earnings or loss in the current financial statements and therefore the Company reports its portion of earnings or loss on a quarter lag. As of June 30, 2016, the carrying value of the Company’s investment in NantStem was approximately $18.2 million. NantStem recorded a total net income of $739,000 for the three months ended March 31, 2016 and a loss of $566,000 for the three months ended December 31, 2015. For the three and six months ended June 30, 2016, the Company recorded $148,000 and $34,000, respectively, in income from NantStem in income (loss) on equity investments on the consolidated statement of operations. As of March 31, 2016, NantStem had $80.3 million in current assets and $142,000 in current liabilities. Shanghai Three The Company is accounting for its interest in Shanghai Three-Alliance Biotech Co. LTD (“Shanghai Three”), a China based company, as an equity method investment, due to the significant influence the Company has over the operations of Shanghai Three through its 25% voting interest. The Company’s investment in Shanghai Three is reported in equity method investments on the consolidated balance sheets and its share of Shanghai Three’s income or loss is recorded in income (loss) on equity investments on the consolidated statement of operations. The financial statements of Shanghai Three are not received sufficiently timely for the Company to record its portion of earnings or loss in the current financial statements and therefore the Company reports its portion of earnings or loss on a quarter lag. As of June 30, 2016, the carrying value of the Company’s investment in Shanghai Three was approximately $1.0 million. Shanghai Three incurred no operating expenses for the three months ended March 31, 2016. As of March 31, 2016, Shanghai Three had $540,000 in current assets and $3.0 million in current liabilities. 3SBio In June 2016, the Company and TNK entered into a joint venture agreement with Shenyang Sunshine Pharmaceutical Company Ltd (“3SBio”), a China based company, to develop and commercialize proprietary immunotherapies, including those developed from, including or using TNK’s chimeric antigen receptor T cell (“CAR-T”) technology targeting carcinoembryonic antigen (“CEA”) positive cancers. In June 2016, 3SBio purchased $10.0 million of Company common stock and warrants as part of the Company’s private placement offering. Under the terms of the agreement 3SBio will contribute an initial investment of $10.0 million to the joint venture and TNK will grant the joint venture an exclusive license to the CEA CAR-T technology and two additional CARs for cellular therapy for the Greater China market, including Mainland China, Hong Kong and Macau. 3SBio will own 51% of the joint venture while TNK will own 49%. As of June 30, 2016, funding and operations of the joint venture had not yet begun, as a result no investment has been recorded as of June 30, 2016. Yuhan In March 2016, the Company and Yuhan Corporation, or Yuhan, a South Korea company, entered into an agreement to form a joint venture company called ImmuneOncia Therapeutics, LLC, to develop and commercialize a number of immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors. During the three months ended June 30, 2016, Yuhan purchased $10.0 million of Company common stock and warrants as part of the Company’s private placement offering. Under the terms of the joint venture agreement, Yuhan will contribute an initial investment of $10.0 million to ImmuneOncia, and the Company will grant ImmuneOncia an exclusive license for one of its immune checkpoint antibodies for specified countries while retaining the rights for US, European, and Japanese markets, as well as global rights for ImmuneOncia to two additional antibodies that will be selected by ImmuneOncia from a group of pre-specified antibodies from the Company’s immuno-oncology antibody portfolio. Yuhan will own 51% of ImmuneOncia, while the Company will own 49%. Yuhan’s Chief Scientific Officer Dr. Su Youn Nam will be appointed CEO of ImmuneOncia. As of June 30, 2016, funding and operations of the joint venture had not yet begun, as a result no investment has been recorded as of June 30, 2016.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	8. Goodwill and Intangible Assets As of both June 30, 2016 and December 31, 2015, the Company had goodwill of $20.6 million, respectively. The Company performed a qualitative test for goodwill impairment as of December 31, 2015. Based upon the results of the qualitative testing the Company concluded that it is more-likely-than-not that the fair values of the Company’s goodwill was in excess of its carrying value and therefore performing the first step of the two-step impairment test was unnecessary. No goodwill impairment was recognized for the three or six months ended June 30, 2016 and 2015. The Company’s intangible assets, excluding goodwill, include patent rights, core technologies and customer relationships. Amortization for the intangible June 30, 2016 Gross Carrying Amount Accumulated Amortization Intangibles, net Customer relationships $ 1,320 $ 668 $ 652 Acquired technology 3,410 446 2,964 Patent rights 90 16 74 Total intangible assets $ 4,820 $ 1,130 $ 3,690 December 31, 2015 Gross Carrying Amount Accumulated Amortization Intangibles, net Customer relationships $ 1,320 $ 536 $ 784 Acquired technology 3,410 358 3,052 Patent rights 90 14 76 Total intangible assets $ 4,820 $ 908 $ 3,912 As of June 30, 2016, the remaining weighted average life for identifiable intangible assets is 15 years. Patent rights are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately 19 years from the date of transfer of the rights to the Company in April 2013. Amortization expense for both the three months ended June 30, 2016 and 2015 was $1,250, respectively. Amortization expense for both the six months ended June 30, 2016 and 2015 was $2,500, respectively, which has been included in intangibles amortization. Acquired technology is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately 19 years from the date of acquisition of the technology in December 2013. Amortization expense for both the three months ended June 30, 2016 and 2015 was $44,000, respectively. Amortization expense for both the six months ended June 30, 2016 and 2015 was $88,000, respectively, which has been included in intangibles amortization. Customer relationships are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately five years from the date of acquisition in December 2013. Amortization expense for both the three months ended June 30, 2016 and 2015 was $66,000, respectively. Amortization expense for both the six months ended June 30, 2016 and 2015 was $132,000, respectively, which has been included in intangibles amortization. Estimated future amortization expense related to intangible assets at June 30, 2016 is as follows (in thousands): Years Ending December 31, Amount 2016 (remaining 6 months) $ 223 2017 445 2018 436 2019 181 2020 181 Thereafter 2,224 Total $ 3,690

Significant Agreements and Cont

Significant Agreements and Contracts	6 Months Ended
	Jun. 30, 2016
Significant Agreements And Contracts [Abstract]
Significant Agreements and Contracts	9. Significant Agreements and Contracts License Agreement with The Scripps Research Institute In January 2010, the Company entered into a license agreement, or the TSRI License, with The Scripps Research Institute, or TSRI. Under the TSRI License, TSRI granted the Company an exclusive, worldwide license to certain TSRI patent rights and materials based on quorum sensing for the prevention and treatment of Staphylococcus aureus (“Staph”) infections, including Methicillin-resistant Staph. In consideration for the license, the Company: (i) issued TSRI a warrant for the purchase of common stock, (ii) agreed to pay TSRI a certain annual royalty commencing in the first year after certain patent filing milestones are achieved, (iii) agreed to pay a royalty on any sales of licensed products by the Company or its affiliates and a royalty for any revenues generated by the Company through its sublicense of patent rights and materials licensed from TSRI under the TSRI License. The TSRI License requires the Company to indemnify TSRI for certain breaches of the agreement and other matters customary for license agreements. The parties may terminate the TSRI License at any time by mutual agreement. In addition, the Company may terminate the TSRI License by giving 60 days’ notice to TSRI and TSRI may terminate the TSRI License immediately in the event of certain breaches of the agreement by the Company or upon the Company’s failure to undertake certain activities in furtherance of commercial development goals. Unless terminated earlier by either or both parties, the term of the TSRI License will continue until the final expiration of all claims covered by the patent rights licensed under the agreement. The warrant was exercised in February 2015. For the three months ended June 30, 2016 and 2015, the Company recorded $2,000 License Agreement with Mabtech Limited I n August 2015, the Company entered into an exclusive licensing agreement to develop and commercialize multiple prespecified biosimilar and biobetter antibodies from Mabtech Limited. Under the terms of the agreement, the Company will develop and market these four monoclonal antibodies (mAbs) for the North American, European and Japanese market. The Company made an initial license payment of $10.0 million and in February 2016, paid an additional $10.0 million license payment, both of which were recognized as acquired in-process research and development expense in the consolidated statements of operations as the Company determined there was no alternative future use for the license. In June 2016, the Company agreed to accelerate and pay a $30.0 million milestone license payment by July 31, 2016, which has been accrued and recognized as acquired in-process research and development expense as of June 30, 3016, in exchange for the purchase by Mabtech Limited and one or more of its affiliates in June 2016, of $20.0 million of Company common stock and warrants. The amended agreement includes additional milestone payments totaling $150.0 million payable over the next three years. License Agreement with NantCell In April 2015, the Company and NantCell entered into a license agreement. Under the terms of the agreement the Company granted an exclusive license to NantCell covering patent rights, know-how, and materials related to certain antibodies, anti-body drug conjugates (ADC) and two CAR-TNK products. NantCell agreed to pay a royalty not to exceed five percent (5%) to the Company on any net sales of products (as defined) from the assets licensed by the Company to NantCell. In addition to the future royalties payable under this agreement, NantCell paid an upfront payment of $10.0 million to the Company and issued 10 million shares of NantCell common stock to the Company valued at $100.0 million based on recent NantCell equity activity with a third party. As of June 30, 2016, the Company had not yet provided all of the items noted in the agreement and therefore has recorded the entire upfront payment and value of the equity interest received as deferred revenue. The Company will recognize the upfront payment and the value of the equity interest received over the expected license period of approximately ten years on a straight line basis. The Company’s ownership interest in NantCell does not provide the Company with control or the ability to exercise significant influence, therefore the $100.0 million investment will be carried at cost in the consolidated balance sheets and evaluated for other-than-temporary impairment on a quarterly basis. NIH Grants In June 2014, the NIAID awarded the Company a Phase II STTR grant to support the advanced preclinical development of human bispecific antibody therapeutics to prevent and treat Staphylococcus aureus S. aureus S. aureus In June 2014, the NIAID awarded the Company a Phase I STTR grant entitled “Anti-Pseudomonas Immunotherapy and Targeted Drug Delivery”. This grant will support the preclinical development of novel anti- Pseudomonas aeruginosa P. aeruginosa In July 2014, the National Cancer Institute (NCI), a division of the NIH, awarded the Company a Phase I STTR grant, entitled “Targeting of Myc-Max Dimerization for the Treatment of Cancer”. This grant will support the preclinical development of the Myc inhibitor, which interferes with the protein-protein interaction (PPI) between Myc and its obligatory dimerization partner, Max, preventing sequence-specific binding to DNA and subsequent initiation of oncogenic transformation. The project period for this Phase I grant covers a one-year period which commenced in August 2014, with total funds available of approximately $225,000. During the three months ended June 30, 2016 and 2015, the Company recorded $0 and $56,000 of revenue, respectively, associated with the Phase I Myc grant award. During the six months ended June 30, 2016 and 2015, the Company recorded $0 and $130,000 of revenue, respectively, associated with the Phase I Myc grant award. In August 2014, the National Heart, Lung, and Blood Institute (NHBLI), a division of the NIH awarded the Company a Phase I Small Business Technology Transfer (SBIR) grant entitled “Human Anti-WISP-1 Antibodies for Treatment of Idiopathic Pulmonary Fibrosis”. This grant will advance the Company’s immunotherapy targeting WNT-1 Inducible Signaling Protein-1(WISP1) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). WISP1 is a protein that has been shown to be upregulated in IPF, linked to key growth factors, cellular proliferation, hyperplasia and is correlated with late stage cancers. IPF is a fatal disease, which results in progressive loss of lung function due to fibrosis of the lungs. The project period for this Phase I grant covers a one-year period which commenced in August 2014, with total funds available of approximately $225,000. During the three months ended June 30, 2016 and 2015, the Company recorded $0 and $21,000 of revenue, respectively, associated with the Phase I WISP1 grant award. During the six months ended June 30, 2016 and 2015, the Company recorded $52,000 and $31,000 of revenue, respectively, associated with the Phase I WISP1 grant award.

Loan and Security Agreement

Loan and Security Agreement	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Loan and Security Agreement	10. Loan and Security Agreement In September 2013, the Company entered into a $5.0 million loan and security agreement with two banks pursuant to which: (i) the lenders provided the Company a term loan which was funded at closing, (ii) the Company repaid its then outstanding equipment loan balance of $762,000, and (iii) the lenders received a warrant to purchase an aggregate 31,250 shares of the Company’s common stock at an exercise price of $8.00 per share exercisable for seven years from the date of issuance. The value of the warrants, totaling $215,000, was recorded as debt discount and additional paid-in capital. In March 2014, the Company entered into an amended and restated loan and security agreement, increasing the September 2013 facility to $12.5 million from $5.0 million, with the same two banks. Such loan was funded at closing and is secured by a lien covering substantially all of the Company’s assets, excluding intellectual property, which is subject to a negative pledge. In October 2014, the Company entered into a second amendment to its amended and restated loan and security agreement to extend the interest only payments on the outstanding amount of the loan from October 1, 2014 to May 1, 2015, after which equal monthly payments of principal and interest are due until the loan maturity date of September 30, 2017. The amended and restated loan: (i) interest rate is 7.95% per annum, and (ii) provided the Lenders additional warrants to purchase an aggregate of 34,642 shares of the Company’s common stock at an exercise price of $12.99 per share, exercisable for seven years from the date of issuance. The value of the warrants, totaling $322,000, was recorded as debt discount and additional paid-in capital. At the Company’s option, it may prepay all of the outstanding principal balance, subject to certain pre-payment fees ranging from 1% to 3% of the prepayment amount. In the event of a final payment of the loans under the loan agreement, either in the event of repayment of the loan at maturity or upon any prepayment, the Company is obligated to pay the amortized portion of the final fee of $781,000. The Company is also subject to certain affirmative and negative covenants under the loan agreement, including limitations on its ability to: undergo certain change of control events; convey, sell, lease, license, transfer or otherwise dispose of any equipment financed by loans under the loan agreement; create, incur, assume, guarantee or be liable with respect to indebtedness, subject to certain exceptions; grant liens on any equipment financed under the loan agreement; and make or permit any payment on specified subordinated debt. In addition, under the loan agreement, subject to certain exceptions, the Company is required to maintain with the lender its primary operating, other deposit and securities accounts. Long-term debt and unamortized discount balances are as follows (in thousands): Face value of amended and restated loan $ 6,974 Fair value of all warrants (536 ) Accretion of debt discount 430 Balance at June 30, 2016 $ 6,868 Future minimum payments under the amended and restated loan and security agreement are as follows (in thousands): Year Ending December 31, 2016 $ 2,748 2017 4,579 Total future minimum payments 7,327 Unamortized interest (353 ) Debt discount (106 ) Total minimum payment 6,868 Current portion (5,067 ) Long-term debt $ 1,801

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Stockholders' Equity	11. Stockholders’ Equity Common Stock The Company has a Sales Agreement with MLV & Co. LLC, ("MLV") to permit the sale by MLV, acting as its sales agent, of up to $50.0 million in additional shares of the Company's common stock from time to time in an at-the-market offering under the Sales Agreement. All sales of shares have been and will continue to be made pursuant to an effective shelf registration statement on Form S-3 filed with the SEC. The Company pays MLV a commission of approximately 2% of the aggregate gross proceeds the Company receives from all sales of the Company's common stock under the Sales Agreement. There were net proceeds on sales of approximately $3.5 million at a weighted average price of $6.37 under the Sales Agreement during the three months ended March 31, 2016. There was no sales activity under the Sales Agreement during the three months ended June 30, 2016 or during the six months ended June 30, 2015. During the three months ended June 30, 2016 the Company closed its private placement offering of common stock and warrants with Yuhan Corporation, Ally Bridge Group ("ABG"), together with Beijing Shijilongxin Investment Co., Ltd. ("Beijing Shijilongxin"), and FREJOY Investment Management Co., Ltd. ("Frejoy"). The Company collectively sold 27,027,027 shares of common stock at $5.55 per share, and warrants to purchase 5,290,936 shares of common stock for total consideration of $150.0 million. The Company incurred $4.2 million in offering commissions and expenses which have been netted against the gross proceeds. The warrants are exercisable for three years at an exercise price of $8.50 per share. The Company received consideration in the form of secured promissory notes for 9,640,060 shares totaling $53.5 million. In July 2016, the Company received a partial payment with accrued interest from one investor totaling $10.0 million and as of June 30, 2016, has recorded this as notes receivable on the consolidated balance sheets. The remaining $43.5 million in notes are reflected as a stock subscription receivable in the Company’s consolidated balance

Stock Incentive Plans

Stock Incentive Plans	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Stock Incentive Plans	12. Stock Incentive Plans 2009 Non-Employee Director Grants In September 2009, prior to the adoption of the 2009 Stock Incentive Plan, the Company’s Board of Directors approved the reservation and issuance of 8,000 nonstatutory stock options to the Company’s non-employee directors. The options vested on the one year anniversary of the vesting commencement date in October 2010, and were exercisable for up to 10 years from the grant date. No further shares may be granted under this plan and, as of June 30, 2016, all options had been cancelled and no 2009 Stock Incentive Plan In October 2009, the Company’s stockholders approved the 2009 Stock Incentive Plan. In June 2016, the Company’s stockholders approved, among other items, the amendment and restatement of the 2009 Stock Incentive Plan, or the Stock Plan, to increase the number of common shares authorized to be issued pursuant to the Stock Plan to 6,260,000. Such shares of the Company’s common stock are reserved for issuance to employees, non-employee directors and consultants of the Company. The Stock Plan provides for the grant of incentive stock options, non-incentive stock options, stock appreciation rights, restricted stock awards, unrestricted stock awards, restricted stock unit awards and performance awards to eligible recipients. Recipients of stock options shall be eligible to purchase shares of the Company’s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the Stock Plan is ten years. Employee option grants will generally vest 25% on the first anniversary of the original vesting commencement date, with the balance vesting monthly over the remaining three years. The vesting schedules for grants to non-employee directors and consultants will be determined by the Company’s Compensation Committee. The following table summarizes stock option activity as of June 30, 2016 and the changes for the period then ended (dollar values in thousands): Options Outstanding Weighted- Average Exercise Price Aggregate Intrinsic Value Outstanding at December 31, 2015 2,957,616 $ 8.95 $ 4,506 Options Granted 462,950 $ 5.86 Options Canceled (443,481 ) $ 8.73 Options Exercised (89,976 ) $ 4.76 Outstanding at June 30, 2016 2,887,109 $ 8.62 $ 934 The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. The fair value of employee stock options was estimated at the grant date using the following assumptions: Six Months Ended June 30, 2016 2015 Weighted-average grant date fair value $ 5.86 $ 11.56 Dividend yield — — Volatility 75 % 75 % Risk-free interest rate 1.45 % 1.65 % Expected life of options 6.1 years 6.1 years The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. Due to the Company’s limited historical data, the estimated volatility incorporates the historical and implied volatility of comparable companies whose share prices are publicly available. The risk-free interest rate assumption was based on the U.S. Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options. The total employee and director stock-based compensation recorded as operating expenses was $1,082,000 and $801,000 for the three months ended June 31, 2016 and 2015, and $2,120,000 and $1,783,000 for the six months ended June 30, 2016 and 2015, respectively. The total unrecognized compensation cost related to unvested stock option grants as of June 30, 2016 was $6,206,000 and the weighted average period over which these grants are expected to vest is 2.8 years. The Company records equity instruments issued to non-employees as expense at their fair value over the related service period as determined in accordance with the authoritative guidance and periodically revalues the equity instruments as they vest. Stock-based compensation expense related to non-employee consultants recorded as operating expenses was $44,000 and $571,000 for the three months ended June 30, 2016 and 2015, and $96,000 and $992,000 for the six months ended June 30, 2016 and 2015, respectively. Common Stock Reserved for Future Issuance Common stock reserved for future issuance consists of the following at June 30, 2016: Common stock warrants outstanding under the underwriters agreement 182,600 Common stock warrants outstanding under the loan and security agreement 65,892 Common stock warrants outstanding under the Cambridge securities agreement 1,724,138 Common stock warrants outstanding under the private placement security agreements 5,290,936 Authorized for future grant or issuance under the amended and restated 2009 Stock Incentive Plan 2,919,703 Issuable under BDL and CARgenix acquisition agreements 619,834 Issuable under assignment agreement based upon achievement of certain milestones 80,000 10,883,103 Subsidiary Equity Grants In May 2015, the Company’s subsidiary TNK Therapeutics, Inc., or TNK, adopted the TNK 2015 Stock Option Plan and reserved 10.0 million shares of TNK class A common stock. During the three and six months ended June 30, 2016, TNK awarded zero and 402,000 options, respectively, with a weighted average grant date fair value of $0.84 per share to certain Company personnel, directors and consultants under such plan. During the three months ended June 30, 2016, TNK cancelled 100,000 options. Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years. As of June 30, 2016, approximately 2.9 million options were outstanding. In May 2015, TNK granted a warrant to the Company’s CEO to purchase 9.5 million shares of TNK class B common stock which have 10 to 1 voting rights. Warrant shares totaling 4.0 million are exercisable evenly over forty months and the remaining warrant shares are exercisable if certain defined events occur within four years from date of issuance at an initial exercise price of $0.01 per share. The exercise price of the warrant is subject to customary adjustment provisions for stock splits, stock dividends, recapitalizations and the like. As of June 30, 2016, 9.5 million warrants were outstanding. In May 2015, the Company’s subsidiary LA Cell, Inc., or LA Cell, adopted the LA Cell 2015 Stock Option Plan and reserved 10.0 million shares of LA Cell class A common stock. During the three and six months ended June 30, 2016, LA Cell awarded zero and 401,500 options, respectively, with a weighted average grant date fair value of $0.20 per share to certain Company personnel, directors and consultants under such plan. During the three months ended June 30, 2016, LA Cell cancelled 201,500 options. Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years. As of June 30, 2016, approximately 1.9 million options were outstanding. In May 2015, LA Cell granted a warrant to the Company’s CEO to purchase 9.5 million shares of LA Cell class B common stock which have 10 to 1 voting rights. Warrant shares totaling 4.0 million are exercisable evenly over forty months and the remaining warrant shares are exercisable if certain defined events occur within four years from date of issuance at an initial exercise price of $0.01 per share. The exercise price of the warrant is subject to customary adjustment provisions for stock splits, stock dividends, recapitalizations and the like. As of June 30, 2016, 9.5 million warrants were outstanding. In October 2015, the Company’s subsidiary Concortis Biosystems, Corp., or CBC, adopted the CBC 2015 Stock Option Plan and reserved 10.0 million shares of CBC class A common stock. During the three and six months ended June 30, 2016, CBC awarded zero and 9,750 options, respectively, with a weighted average grant date fair value of $0.17 per share to certain Company personnel under such plan. During the three and six months ended June 30, 2016, zero and 420,000 options were cancelled by CBC, respectively. Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years. As of June 30, 2016, approximately 1.8 million options were outstanding. In October 2015, CBC granted a warrant to the Company’s CEO to purchase 9.5 million shares of CBC class B common stock which have 10 to 1 voting rights. Warrant shares totaling 4.0 million are exercisable evenly over forty months and the remaining warrant shares are exercisable if certain defined events occur within four years from date of issuance at an initial exercise price of $0.25 per share. The exercise price of the warrant is subject to customary adjustment provisions for stock splits, stock dividends, recapitalizations and the like. As of June 30, 2016, 9.5 million warrants were outstanding. In October 2015, the Company’s subsidiary Scintilla Pharmaceuticals, Inc., or Scintilla, adopted the Scintilla 2015 Stock Option Plan and reserved 10.0 million shares of Scintilla class A common stock. During the three and six months ended June 30, 2016, Scintilla awarded zero and 2,000 options, respectively, with a weighted average grant date fair value of $0.01 per share to certain Company personnel under such plan. During the three and six months ended June 30, 2016, zero and 200,000 options were cancelled by Scintilla, respectively. Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years. As of June 30, 2016, approximately 1.0 million options were outstanding. In October 2015, Scintilla granted a warrant to the Company’s CEO to purchase 9.5 million shares of Scintilla class B common stock which have 10 to 1 voting rights. Warrant shares totaling 4.0 million are exercisable evenly over forty months and the remaining warrant shares are exercisable if certain defined events occur within four years from date of issuance at an initial exercise price of $0.01 per share. The exercise price of the warrant is subject to customary adjustment provisions for stock splits, stock dividends, recapitalizations and the like. As of June 30, 2016, 9.5 million warrants were outstanding. In October 2015, the Company’s subsidiary Sorrento Biologics, Inc., or Biologics, adopted the Biologics 2015 Stock Option Plan and reserved 10.0 million shares of Biologics class A common stock. No options were awarded or cancelled during the three and six months ended June 30, 2016 under such plan. Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years. As of June 30, 2016, approximately 1.4 million options were outstanding. In October 2015, Biologics granted a warrant to the Company’s CEO to purchase 9.5 million shares of Biologics class B common stock which have 10 to 1 voting rights. Warrant shares totaling 4.0 million are exercisable evenly over forty months and the remaining warrant shares are exercisable if certain defined events occur within four years from date of issuance at an initial exercise price of $0.01 per share. The exercise price of the warrant is subject to customary adjustment provisions for stock splits, stock dividends, recapitalizations and the like. As of June 30, 2016, 9.5 million warrants were outstanding. The total director stock-based compensation recorded as operating expenses by the Company for TNK, LA Cell, CBC, Scintilla and Biologics was $41,000 and $0 for the three months ended June 30, 2016 and 2015 and was $83,000 and $0 for the six months ended June 30, 2016 and 2015, respectively. Total unrecognized stock-based compensation expense related to unvested director stock option and warrant grants for these entities as of June 30, 2016 was $451,000, and the weighted-average period over which these grants are expected to vest is approximately 3.2 years. The Company records equity instruments issued to non-employees as expense at their fair value over the related service period as determined in accordance with the authoritative guidance and periodically revalues the equity instruments as they vest. Stock based compensation expense related to non-employee consultants recorded as operating expenses by the Company for TNK, LA Cell, CBC, Scintilla and Biologics was $44,000 and $0 for the three months ended June 30, 2016 and 2015 and was $92,000 and $0 for the six months ended June 30, 2016 and 2015, respectively. The weighted-average assumptions used in the Black-Scholes option and warrant pricing model used by TNK, LA Cell, CBC, Scintilla and Biologics to determine the fair value of stock option grants for directors and non-employee consultants for the six months ended June 30, 2016 were as follows: expected dividend yield – 0%, risk-free interest rate – 1.39% to 1.74%, expected volatility – 75% to 77%, and expected term of 4.0 to 6.1 years. In May 2014, the Company’s subsidiary Ark Animal Health, Inc., or Ark, adopted the Ark 2014 Stock Option Plan and reserved and awarded 600,000 options to certain directors and consultants under such plan. Stock options granted under such plan typically vest a portion immediately upon grant and the remaining options over one year from the grant date and will have a contractual term of ten years. As of June 30, 2016, 351,000 options were outstanding. The total director and consultant stock-based compensation recorded as operating expenses by the Company for Ark for the three months ended June 30, 2016 and 2015 was $0 and $22,000 and was $0 and $55,000 for the six months ended June 30, 2016 and 2015, respectively. No unrecognized stock-based compensation expense related to unvested stock option grants existed as of June 30, 2016.

Investment in Variable Interest

Investment in Variable Interest Entity	6 Months Ended
	Jun. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Investment in Variable Interest Entity	13. Investment in Variable Interest Entity The Company’s consolidated financial statements include the financial results of LA Cell, Inc. (LA Cell), a consolidated subsidiary of the Company and a variable interest entity in which the Company is the primary beneficiary. In September 2015, LA Cell exclusively licensed certain technology from City of Hope. The technology includes cell-penetrating antibody therapies that enables modified monoclonal antibodies (mAbs) to penetrate into cells and target disease-causing molecules. Utilizing mAbs derived from the Company's antibody portfolio, LA Cell is focused on developing therapies against important oncology targets, including but not limited to c-MYC, mutated KRAS, STAT3, and FoxP3. Pursuant to the license agreement, LA Cell made a $2.0 million upfront payment to City of Hope and has paid additional license payments of $5.0 million to City of Hope as of June 30, 2016. The license agreement also provides for development and sales milestone payments and royalties based on net sales, as defined in the license agreement. Upon the formation of LA Cell, the Company held all of the outstanding stock of LA Cell. As of June 30, 2016, the Company held an aggregate of approximately a 48% ownership of outstanding shares but which include a majority of the voting rights. For the three and six months ended June 30, 2016, LA Cell recognized $3.0 million and $5.0 million, respectively, in acquired in-process research and development expense in the Company’s consolidated statements of operations and incurred minimal general and administrative expenses.

Derivative Liability

Derivative Liability	6 Months Ended
	Jun. 30, 2016
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Liability	14. Derivative Liability On October 13, 2015, the Company wrote a call option to Cambridge Equities, LP (Cambridge), a related party, on up to 2.0 million shares of NantKwest, Inc., (NantKwest) common stock held by the Company (the Option Agreement). As of June 30, 2016, the Company holds approximately 5.6 million shares of common stock of NantKwest, par value $.0001 per share, which is classified as available-for-sale and reported in its consolidated financial statements as marketable securities. The Option Agreement gave Cambridge the right to purchase up to 2.0 million shares at a price of $15.295 per share from time to time during the first quarter of 2016. There is no contractual option premium associated with this Option Agreement. The Option Agreement is a derivative as defined in ASC 815 and is recognized at fair value every reporting period the Option Agreement is in effect, with changes in fair value recognized in current operations. The call option expired unexercised on March 31, 2016 and for the three and six months ended June 30, 2016 the Company recorded a gain of $0 and $5.5 million, respectively, upon the cancelation of the derivative liability. As of June 30, 2016 no derivative liability was recorded on the Company’s consolidated balance sheets .

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	15. Income Taxes The Company maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and temporary differences. In assessing the Company's ability to realize deferred tax assets, management considers, on a periodic basis, whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. As such, management has determined that it is appropriate to maintain a full valuation allowance against the Company's U.S. federal and state deferred tax assets, with the exception of an amount equal to its deferred tax liabilities, which can be expected to reverse over a definite life. The Company is subject to taxation in the U.S. and various state jurisdictions. The Company's tax years for 2007 and later are subject to examination by the U.S. and state tax authorities due to the existence of the NOL carryforwards. As of the June 30, 2016, the Company had approximately $1.8 million of unrecognized tax benefits that, if recognized, would impact the effective income tax rate for continuing operations, subject to possible offset by an increase in the deferred tax asset valuation allowance. As of June 30, 2015, there were no unrecognized tax benefits. The Company recognizes interest and penalties related to unrecognized tax benefits in its provision for income taxes. For the three and six months ended June 30, 2016 and 2015, no expense was recorded related to interest and penalties. The Company believes that no significant amount of the liabilities for uncertain tax positions will expire within twelve months of June 30, 2016.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies Litigation In the normal course of business, the Company may be named as a defendant in one or more lawsuits. The Company is not a party to any outstanding material litigation and management is currently not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to its financial condition or results of operations. On April 25, 2016, Wildcat Liquid Alpha, LLC (“WLA”) filed a complaint in the Court of Chancery of the State of Delaware seeking an order compelling the Company to provide WLA with certain documents, books and records for inspection and copying pursuant to an April 11, 2016 demand made by WLA. The Company believes that WLA’s April 11, 2016 demand for documents and the corresponding litigation are deficient and without merit, and will vigorously defend itself against both. The Company is unable to determine whether any loss will occur with respect to this matter or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by the Company as of the date of filing of this Quarterly Report on Form 10-Q. Furthermore, there is no guarantee that the Company will prevail in this action or receive any relief if it does prevail. On May 13, 2016, WLA filed a derivative action in the Court of Chancery of the State of Delaware against each of the members of the Board and against the Company as nominal defendant alleging, among other things: (1) breach of fiduciary duty with respect to the Company’s prior announcement of four transactions through which investors agreed to purchase up to $150 million of shares of our common stock and warrants; (2) breach of fiduciary duty with respect to the formation of, and certain options and warrants issued by, certain of the Company’s subsidiaries to Dr. Ji and members of the Board; (3) waste of corporate assets; (4) unjust enrichment; and (5) mismanagement, including questioning the Company’s decisions to make passive investments in other corporations (the “Derivative Action”). The Company believes that the Derivative Action is without merit, and will vigorously defend itself against the action. The Company is unable to determine whether any loss will occur with respect to the Derivative Action or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by the Company as of the date of filing of this Quarterly Report on Form 10-Q. Furthermore, there is no guarantee that the Company will prevail in this suit or receive any damages or other relief if it does prevail Operating Leases The Company currently leases in San Diego, California approximately 43,000 square feet of corporate office and laboratory space, approximately 10,875 square feet of laboratory and office space at a second location and approximately 6,350 square feet of laboratory and office space at a third location. The Company’s lease agreements in San Diego, as amended, for its corporate office and laboratory space and its second laboratory and office space, expire in December 2025, April 2017 and June 2018, respectively. For all leased properties the Company has provided a total security deposit of $346,000 to secure its obligations under the various leases, which has been included in prepaid and other assets.

Related Party Agreements

Related Party Agreements	6 Months Ended
	Jun. 30, 2016
Related Party Transactions [Abstract]
Related Party Agreements	17. Related Party Agreements During the three and six months June 30, 2016 and 2015, the Company purchased products totaling $0 and $117,000 and $350,000 and $415,000, respectively, from Levena Biopharma Co., LTD (Levena), a Chinese Corporation. The Company’s former Senior Vice President and Head of Antibody Drug Conjugates was one of the owners of Levena. Levena ceased to be a related party during the first quarter of 2016. In December 2014, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with Cambridge Equities, LP (Cambridge), an affiliated entity of Dr. Patrick Soon-Shiong (the “Investor”) pursuant to which the Company agreed to issue and sell to the Investor an aggregate of approximately 7.2 million shares of the Company’s common stock at a price of $5.80 per share for an aggregate purchase price of $41.7 million. In connection with the Purchase Agreement, the Investor received a warrant to purchase approximately 1.7 million shares of the Company’s Common Stock. The warrant is exercisable for a period of three years from the date of issuance at an initial exercise price of $5.80 per share. In December 2014, the Company entered into a joint development and license agreement with Conkwest Inc., which has changed its name to NantKwest, and of which Dr. Patrick Soon-Shiong is a majority owner. In addition, the Company purchased approximately 5.6 million shares of NantKwest common stock for $10.0 million. Subsequent to June 30, 2016, the Company closed a transaction with the Chan Soon-Shiong Family Foundation and Cambridge Equities, LP to sell all of its investment in NantKwest, Inc. held by the Company. See Note 19. As described more fully in Notes 7 and 9, during 2015, the Company entered into a joint venture called Immunotherapy NANTibody, LLC, with NantCell, a wholly-owned subsidiary of NantWorks, a private company owned by Dr. Patrick Soon-Shiong. In July 2015, the Company contributed its portion of the initial joint funding of $40.0 million to the Immunotherapy NANTibody joint venture. The Company and NantCell have also entered into a license agreement pursuant to which the Company received a $10.0 million upfront license payment and $100.0 million of vested NantCell common stock. As of June 30, 2016, the Company had not yet provided all of the items noted in the agreement and therefore has recorded the entire upfront payment and value of the equity interest received as deferred revenue. As described more fully in Notes 7 and 14, t he In connection with negotiated changes to the structure of NantStem the Company issued a call option on shares of NantKwest that it owned to Cambridge, a related party to the Company and to NantBioScience. The call option In May 2015, the Company entered into a stock sale and purchase agreement with NantPharma, a private company owned by NantWorks pursuant to which the Company sold its equity interests in IgDraSol, its wholly-owned subsidiary and holder of the rights to Cynviloq for an upfront payment of $90.05 million and potential regulatory and sales milestones of up to $1.2 billion. As described more fully in Note 9, in June 2016, the Company agreed to accelerate and pay a $30.0 million milestone license payment by July 31, 2016, which has been accrued and recognized as acquired in-process research and development expense as of June 30, 2016, in exchange for the purchase by Mabtech Limited and one or more of its affiliates in June 2016, of $20.0 million of Company common stock and warrants. As described more fully in Note 7, in March 2016, the Company and Yuhan entered into an agreement to form a joint venture company called ImmuneOncia Therapeutics, LLC, to develop and commercialize a number of immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors. During the three months ended June 30, 2016, Yuhan purchased $10.0 million of Company common stock and warrants. As described more fully in Note 7, in June 2016, the Company and TNK entered into a joint venture agreement with 3SBio to develop and commercialize proprietary immunotherapies, including those developed from, including or using TNK’s chimeric antigen receptor T cell (“CAR-T”) technology targeting carcinoembryonic antigen (“CEA”) positive cancers. In June 2016, 3SBio purchased $10.0 million of Company common stock and warrants.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent Events Subsequent to June 30, 2016, the Company completed a letter agreement with the Chan Soon-Shiong Family Foundation (“Foundation”) and Cambridge Equities, LP (“Cambridge”) (the “Letter Agreement”). Pursuant to the terms of the Letter Agreement, among other things, (a) the Company agreed to sell to Foundation, and Foundation agreed to purchase from the Company, an aggregate of 5,618,326 shares of common stock of NantKwest, Inc. held by the Company, (b) Foundation agreed to sell to the Company, and the Company agreed to purchase all reported shares held by Foundation and Cambridge, an aggregate of 7,878,098 shares of common stock of the Company (“Common Stock”) held by Foundation and Cambridge, (c) Cambridge agreed to forfeit its right to purchase 500,000 shares of Common Stock issuable pursuant a warrant to purchase 1,724,138 shares of Common Stock held by Cambridge, and (d) the Company agreed to pay to Foundation an aggregate of approximately $15.64 million. The transactions contemplated under the Letter Agreement closed on July 7, 2016. Effective with the close of the transaction in July 2016, the Company will retire the 7,878,098 shares and has the ability to sell these shares for additional funds. On July 11, 2016 the Company announced a license and collaboration agreement with Les Laboratoires Servier, SAS, a corporation incorporated under the laws of France, and Institut de Recherches Internationales Servier, a company duly organized and existing under the laws of France (individually and collectively, “Servier”) for the development, manufacture and commercialization of products using Sorrento's fully human immuno-oncology anti-PD-1 monoclonal antibody (mAb) STI-A1110. Pursuant to the financial terms of that agreement the Company received a non-refundable up-front payment of $27.4 million in July of 2016. On August 2, 2016, the Company, its subsidiary Scintilla Pharmaceuticals, Inc., (“Scintilla”), and Scilex Pharmaceuticals, Inc. (“Scilex”) entered into a binding term sheet (the “Binding Term Sheet”) setting forth the terms and conditions by which Scintilla will, through a subsidiary, purchase all of the issued and outstanding equity of Scilex (the “Acquisition”). Subject to certain conditions, and in exchange for all of the issued and outstanding equity of Scilex, Scintilla will: (1) at the closing of the Acquisition (the “Closing”), pay to the equityholders of Scilex an aggregate of $100.00 (the “Cash Consideration”), and (2) following the earlier to occur of (a) the closing of the next third party equity financing of Scintilla or the initial public offering of shares of common stock of Scintilla (“Scintilla Common Stock”) in the United States (a “Financing”), or (b) the two-year anniversary of the Closing, issue to the equityholders of Scilex an aggregate of $70,000,000 of shares of Scintilla Common Stock, subject to adjustment in certain circumstances, based upon the valuation of Scintilla immediately after such Financing or otherwise as of the two-year anniversary of the Closing (the “Stock Consideration”); however, 20% of the Stock Consideration will be placed into escrow, a portion of which will be held for a period of up to six or 12 months to secure certain obligations of Scilex and its equityholders in connection with the Acquisition. The Cash Consideration and the Stock Consideration will be paid to the Scilex equityholders on a pro rata The final terms of the Acquisition are subject to the negotiation and finalization of the definitive agreements relating to the Acquisition and the material terms of the Acquisition may differ from those set forth in the Binding Term Sheet. In addition, the Closing will be subject to various customary and other closing conditions.

Significant Accounting Polici25

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Nature of Operations and Basis of Presentation	Nature of Operations and Basis of Presentation Sorrento Therapeutics, Inc. (NASDAQ: SRNE), together with its subsidiaries (collectively, the “Company”) is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs worldwide. The Company’s primary therapeutic focus is oncology, including the treatment of chronic cancer pain, but is also developing therapeutic products for other indications, including immunology and infectious diseases. The Company currently has multiple clinical development programs underway: (i) Chimeric Antigen Receptor-T Cell (“CAR-T”) programs for solid tumors, (ii) resiniferatoxin, or RTX, a non-opiate, ultra-potent and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease, and (iii) its clinical development programs for its biosimilar/biobetter antibodies. The Company’s pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including its biosimilars/biobetters, its fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its proprietary G-MAB ® ® Through June 30, 2016, the Company had devoted substantially all of its efforts to research and product development, raising capital and building infrastructure, and had not realized revenues from its planned principal operations. The accompanying interim consolidated financial statements have been prepared by the Company, without audit, in accordance with the instructions to Form 10-Q and, therefore, do not necessarily include all information and footnotes necessary for a fair statement of its financial position, results of operations and cash flows in accordance with United States generally accepted accounting principles (GAAP). The accompanying consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries and those of a variable interest entity where the Company is the primary beneficiary. For consolidated entities where the Company owns or are exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Sorrento Therapeutics, Inc. Hong Kong Limited had no operating activity through June 2016. All intercompany balances and transactions have been eliminated in consolidation. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way the Company accounts for its existing collaborative relationships and other arrangements. The Company continuously assesses whether it is the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the Company consolidating or deconsolidating one or more of its collaborators or partners. The balance sheet at December 31, 2015 is derived from the audited consolidated financial statements at that date which are not presented herein. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of financial position, results of operations and cash flows. These consolidated financial statements should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015. Operating results for interim periods are not expected to be indicative of operating results for the Company’s 2016 fiscal year.
Liquidity	Liquidity The Company anticipates that it will continue to incur net losses in the foreseeable future as it (i) advances clinical stage product candidates such as biosimilar/biobetter antibodies, CAR-T programs and RTX in the clinic and potentially pursues other development, (ii) continues to identify a number of potential mAb and ADC drug candidates and further advances various preclinical and development activities, (iii) advances its product candidates into the clinic, (iv) invests in additional joint ventures or third party collaboration or acquisition agreements, and (v) expands corporate infrastructure, including the costs associated with being a NASDAQ listed public company. Based on currently available resources, the Company believes it has the ability to meet all obligations due over the course of the next twelve months. On April 3, 2016, the Company entered into a Securities Purchase Agreement (the “ABG Purchase Agreement”) with ABG SRNE Limited and Ally Bridge LB Healthcare Master Fund Limited (collectively, “Ally Bridge”), pursuant to which, among other things, the Company agreed to issue and sell to Ally Bridge and other purchasers that may be designated by Ally Bridge (collectively, the “ABG Purchasers”), in a private placement transaction (the “ABG Private Placement”), up to $50.0 million in shares of common stock of the Company (“Common Stock”) and warrants to purchase shares of Common Stock. Upon the closing of the ABG Private Placement, the Company will issue to each ABG Purchaser (1) such number of shares (the “ABG Shares”) of Common Stock as is equal to the amount of such ABG Purchaser’s investment divided by $5.55, provided that Under the terms of the ABG Purchase Agreement, the Company is obligated to prepare and file with the Securities and Exchange Commission (the “SEC”), within 30 days of the closing date of the ABG Private Placement, a registration statement to register for resale the ABG Shares and the shares of Common Stock issuable upon exercise of each ABG Warrant (the “ABG Warrant Shares”), and may be required to effect certain registrations to register for resale the ABG Shares and the ABG Warrant Shares in connection with certain “piggy-back” registration rights granted to the ABG Purchasers. On April 3, 2016, the Company also entered into a Securities Purchase Agreement (collectively, the “Additional Purchase Agreements”) with each of Beijing Shijilongxin Investment Co., Ltd. ( “Beijing Shijilongxin”), FREJOY Investment Management Co., Ltd. (“Frejoy”) and Yuhan Corporation (“Yuhan”), pursuant to which, among other things, the Company agreed to issue and sell, in separate private placement transactions: (1) to Beijing Shijilongxin, 8,108,108 shares of Common Stock, and a warrant to purchase 1,176,471 shares of Common Stock, for an aggregate purchase price of $45.0 million; (2) to Frejoy, 8,108,108 shares of Common Stock, and a warrant to purchase 1,176,471 shares of Common Stock, for an aggregate purchase price of $45.0 million; and (3) to Yuhan, 1,801,802 shares of Common Stock, and a warrant to purchase 235,294 shares of Common Stock, for an aggregate purchase price of $10.0 million. The warrants to be issued pursuant to each of the Additional Purchase Agreements (collectively, the “Additional Warrants” and, together with each ABG Warrant, the “Warrants”) will have an exercise price of $8.50 per share, will be immediately exercisable upon issuance, will have a term of three years and will be exercisable on a cash or cashless exercise basis. Under the terms of the Additional Purchase Agreements, each of Beijing Shijilongxin, Frejoy and Yuhan has the right to demand, at any time beginning six months after the closing of the transactions contemplated by the applicable Additional Purchase Agreement, that the Company prepare and file with the SEC a registration statement to register for resale such investor’s shares of Common Stock purchased pursuant to the applicable Additional Purchase Agreement and the shares of Common Stock issuable upon exercise of such investor’s Additional Warrant. In addition, the Company may be required to effect certain registrations to register for resale such shares in connection with certain “piggy-back” registration rights granted to Beijing Shijilongxin, Frejoy and Yuhan. On May 2, 2016 the Company announced that it closed its previously announced private placement financing of common stock and warrants with Yuhan Corporation for gross proceeds of $10.0 million. Yuhan purchased 1,801,802 shares of common stock at $5.55 per share and a warrant to purchase 235,294 shares of common stock. The warrant is exercisable for three years at an exercise price of $8.50 per share. On June 8, 2016 the Company announced that is closed on the remainder of the $150.0 million financing. Ally Bridge Group ("ABG"), a global healthcare-focused investment group based in Hong Kong, led the financing and, together with Beijing Shijilongxin Investment Co., Ltd. ("Beijing Shijilongxin"), and FREJOY Investment Management Co., Ltd. ("Frejoy") collectively purchased 25,225,221 shares of common stock at $5.55 per share, and warrants to purchase 5,055,642 shares of common stock for total consideration of $140.0 million. The Company plans to continue to fund its operating losses and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. On July 11, 2016 the Company announced a license and collaboration agreement with Les Laboratoires Servier, SAS, a corporation incorporated under the laws of France, and Institut de Recherches Internationales Servier, a company duly organized and existing under the laws of France (individually and collectively, “Servier”) for the development, manufacture and commercialization of products using Sorrento's fully human immuno-oncology anti-PD-1 monoclonal antibody (mAb) STI-A1110. Pursuant to the financial terms of that agreement the Company received a non-refundable up-front payment of $27.4 million in July of 2016. The Company filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (“SEC”), which was declared effective by the SEC in July 2013 (the “2013 Shelf Registration Statement”). The 2013 Shelf Registration Statement provides the Company the ability to offer up to $100.0 million of securities, including equity and other securities as described in the registration statement. After the May 2014 underwritten offering the Company has the ability to offer up to $36.6 million of additional securities under the 2013 Shelf Registration Statement. In November 2014, the Company filed a universal shelf registration statement on Form S-3 with the SEC, which was declared effective by the SEC in December 2014 (the “2014 Shelf Registration Statement”). The 2014 Shelf Registration Statement provides the Company with the ability to offer up to $250.0 million of securities, including equity and other securities as described in the registration statement. Included in the 2014 Shelf Registration Statement is a sales agreement prospectus covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $50.0 million of the Company’s common stock that may be issued and sold under a sales agreement with MLV & Co. LLC (the “ATM Facility”). Subsequent to June 30, 2016, the Company completed a letter agreement with the Chan Soon-Shiong Family Foundation (“Foundation”) and Cambridge Equities, LP (“Cambridge”) (the “Letter Agreement”). Pursuant to the terms of the Letter Agreement, among other things, (a) the Company agreed to sell to Foundation, and Foundation agreed to purchase from the Company, an aggregate of 5,618,326 shares of common stock of NantKwest, Inc. held by the Company, (b) Foundation agreed to sell to the Company, and the Company agreed to purchase all reported shares held by Foundation and Cambridge, an aggregate of 7,878,098 shares of common stock of the Company (“Common Stock”) held by Foundation and Cambridge, (c) Cambridge agreed to forfeit its right to purchase 500,000 shares of Common Stock issuable pursuant a warrant to purchase 1,724,138 shares of Common Stock held by Cambridge, and (d) the Company agreed to pay to Foundation an aggregate of approximately $15.6 million. The transactions contemplated under the Letter Agreement closed on July 7, 2016. Effective with the close of the transaction in July 2016, the Company will retire the 7,878,098 shares and has the ability to sell these shares for additional funds. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial covenants that may restrict the Company’s ability to operate its business.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including those related to the valuation of warrants, stock-based compensation and the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments: · Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments. · Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace. · Level 3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange. The carrying amounts of cash equivalents and marketable securities approximate their fair value based upon quoted market prices. Certain of our financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, accounts receivable and payable, and other financial instruments in current assets or current liabilities.
Marketable Securities	Marketable Securities Marketable securities are designated as available-for-sale securities and are accounted for at fair value. Marketable securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Marketable securities that are readily available for use in current operations are classified as short-term available-for-sale securities and are reported as a component of current assets in the accompanying consolidated balance sheets. Marketable securities that are not considered available for use in current operations are classified as long-term available-for-sale securities and are reported as a component of long-term assets in the accompanying consolidated balance sheets. Securities that are classified as available-for-sale are carried at fair value, with temporary unrealized gains and losses reported as a component of stockholders' equity until their disposition. The cost of securities sold is based on the specific identification method. All of the Company’s marketable securities are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. For the three and six months ended June 30, 2016, no other-than-temporary impairment charges were recorded.
Grants and Accounts Receivable	Grants and Accounts Receivable Grants receivable at June 30, 2016 and December 31, 2015 represent amounts due under several federal contracts with the National Institute of Allergy and Infectious Diseases, or NIAID, a division of the National Institutes of Health, or NIH, collectively, the NIH Grants. The Company considers the grants receivable to be fully collectible; accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations. Accounts receivable at June 30, 2016 and December 31, 2015 consists of trade receivables from sales and services provided to certain customers, which are generally unsecured and due within 30 days. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for doubtful accounts within grants and accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for doubtful accounts. As of June 30, 2016 and December 31, 2015, the allowance for doubtful accounts was $29,000 and $4,000, respectively.
Property and Equipment	Property and Equipment Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally three to five years. Leasehold improvements are amortized over the lesser of the life of the lease or the life of the asset. Repairs and maintenance are charged to expense as incurred.
Acquisitions and Intangibles	Acquisitions and Intangibles The Company has engaged in business combination activity. The accounting for business combinations requires management to make judgments and estimates of the fair value of assets acquired, including the identification and valuation of intangible assets, as well as liabilities assumed. Such judgments and estimates directly impact the amount of goodwill recognized in connection with each acquisition, as goodwill presents the excess of the purchase price of an acquired business over the fair value of its net tangible and identifiable intangible assets.
Goodwill and Other Long-Lived Assets	Goodwill and Other Long-Lived Assets Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment in the fourth quarter of 2015, noting no impairment. There have not been any triggering events through June 30, 2016. The Company evaluates its long-lived assets with definite lives, such as property and equipment, acquired technology, customer relationships, patent and license rights, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of non-generic and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of the life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets’ book value to future net undiscounted cash flows that the assets are expected to generate. There have not been any impairment losses of long-lived assets through June 30, 2016.
Derivative Liability	Derivative Liability Derivative liabilities are recorded on the consolidated balance sheets at fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. The Company estimates the fair value of derivative liabilities using the Black-Scholes option pricing model.
Investments in Other Entities	Investments in Other Entities The Company holds a portfolio of investments in equity securities that are accounted for under either the equity method or cost method. Investments in entities over which the Company has significant influence but not a controlling interest are accounted for using the equity method, with the Company’s share of earnings or losses reported in other income (expense), net. The Company’s cost method investments are included in investments in common stock on the consolidated balance sheets. The Company’s equity method investments are included in equity method investments on the consolidated balance sheets. All investments are reviewed on a regular basis for possible impairment. If an investment's fair value is determined to be less than its net carrying value and the decline is determined to be other-than-temporary, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an other-than-temporary decline in value has occurred include: market value or exit price of the investment based on either market-quoted prices or future rounds of financing by the investee; length of time that the market value was below its cost basis; financial condition and business prospects of the investee; the Company’s intent and ability to retain the investment for a sufficient period of time to allow for recovery in market value of the investment; issues that raise concerns about the investee's ability to continue as a going concern; any other information that we may be aware of related to the investment. The Company does not report the fair value of its equity investments in non-publicly traded companies because it is not practical to do so.
Research and Development Costs and Collaborations	Research and Development Costs and Collaborations All research and development costs are charged to expense as incurred. Such costs primarily consist of lab supplies, contract services, stock-based compensation expense, salaries and related benefits.
Acquired In-Process Research and Development Expense	Acquired In-Process Research and Development Expense The Company has acquired and may continue to acquire the rights to develop and commercialize new drug candidates. The up-front payments to acquire a new drug compound, as well as future milestone license payments, are immediately expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use.
Income Taxes	Income Taxes The provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740-10, Uncertainty in Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has uncertain tax positions. The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of June 30, 2016 and December 31, 2015, the Company maintained a full valuation allowance against its deferred tax assets, with the exception of an amount equal to its deferred tax liabilities, which can be expected to reverse over a definite life.
Revenue Recognition	Revenue Recognition The Company’s revenues are generated primarily from various NIH grant awards, and from the sale of customized reagents and the provision of contract development services. The revenue from the NIH grant awards is based upon subcontractor and internal costs incurred that are specifically covered by the grant, and where applicable, a facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs internal expenses that are related to the grant. Revenues from sales are generated from the sale of customized reagents which include industrial standard cytotoxins, linkers, and linker-toxins used for preparing ADCs. Contract development services include providing synthetic expertise to customer’s synthesis by delivering proprietary cytotoxins, linkers and linker-toxins and ADC service using industry standard toxin and antibodies provided by customers. Revenue is recognized when, (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the services have been rendered, (iii) the price is fixed or determinable, and (iv) collectability is reasonably assured. License fees for the licensing of product rights are recorded as deferred revenue upon receipt of cash and recognized as revenue on a straight-line basis over the license period. The Company is obligated to accept from customers the return of products sold that are damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the terms of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company has not experienced any sales returns.
Stock-based Compensation	Stock-based Compensation The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is generally measured at the grant date, based on the calculated fair value of the award and an estimate of forfeitures, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant). The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options and restricted stock granted to non-employees is re-measured over the vesting period, and the resulting changes in fair value are recognized as expense in the period of the change in proportion to the services rendered to date.
Net Earnings (Loss) per Share	Net Earnings (Loss) per Share Basic net earnings (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted net earnings (loss) per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options or the exercise of outstanding warrants. The treasury stock method and if-converted method are used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net earnings (loss) per share when their effect is anti-dilutive. In periods where a net loss is presented, all potentially dilutive securities are anti-dilutive and are excluded from the computation of diluted net loss per share.
Comprehensive Income (Loss)	Comprehensive Income (Loss ) Comprehensive income (loss) is comprised of net income (loss) and adjustments for the change in unrealized gains and losses on our investments in available-for-sale marketable securities, net of taxes. The Company displays comprehensive income (loss) and its components in its consolidated statements of comprehensive income (loss).
Segment Information	Segment Information The Company is engaged primarily in the discovery and development of innovative therapies focused on oncology and the treatment of chronic cancer pain as well as immunology and infectious diseases based on its platform technologies. Accordingly, the Company has determined that it operates in one operating segment.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). In April 2016, the FASB issued Accounting Standards Update No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. Revenue from Contracts with Customers (Topic 606), In May 2016, the FASB issued Accounting Standards Update No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients. Revenue from Contracts with Customers (Topic 606), In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents the Company’s financial assets and liabilities that are measured at fair value on a recurring basis. (in thousands): Fair Value Measurements at June 30, 2016 Balance Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Marketable securities $ 34,946 $ 34,946 $ — $ — Total assets $ 34,946 $ 34,946 $ — $ — Fair Value Measurements at December 31, 2015 Balance Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Marketable securities $ 97,366 $ 97,366 $ — $ — Total assets $ 97,366 $ 97,366 $ — $ — Liabilities: Derivative liability $ 5,520 $ — $ — $ 5,520 Total liabilities $ 5,520 $ — $ — $ 5,520
Summary of Derivative Liability Measured at Fair Value Using Significant Unobservable Inputs (Level 3)	The following table includes a summary of the derivative liability measured at fair value using significant unobservable inputs (Level 3) during the six months ended June 30, 2016 (in thousands): Derivative Liability Beginning balance at December 31, 2015 $ 5,520 Gain on expiration of derivative liability (5,520 ) Ending balance at June 30, 2016 $ —

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2016
Investments Debt And Equity Securities [Abstract]
Schedule of Marketable Securities	Marketable securities consisted of the following as of June 30, 2016 (in thousands): June 30, 2016 Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Available-for-sale securities: NantKwest common shares $ 10,000 $ 87,366 $ (62,420 ) $ 34,946

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Company's Identifiable Intangible Assets	A summary of the Company’s identifiable intangible assets is as follows (in thousands): June 30, 2016 Gross Carrying Amount Accumulated Amortization Intangibles, net Customer relationships $ 1,320 $ 668 $ 652 Acquired technology 3,410 446 2,964 Patent rights 90 16 74 Total intangible assets $ 4,820 $ 1,130 $ 3,690 December 31, 2015 Gross Carrying Amount Accumulated Amortization Intangibles, net Customer relationships $ 1,320 $ 536 $ 784 Acquired technology 3,410 358 3,052 Patent rights 90 14 76 Total intangible assets $ 4,820 $ 908 $ 3,912
Schedule of Estimated Future Amortization Expense Related to Intangible Assets	Estimated future amortization expense related to intangible assets at June 30, 2016 is as follows (in thousands): Years Ending December 31, Amount 2016 (remaining 6 months) $ 223 2017 445 2018 436 2019 181 2020 181 Thereafter 2,224 Total $ 3,690

Loan and Security Agreement (Ta

Loan and Security Agreement (Tables)	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Schedule of Long-Term Debt and Unamortized Discount Balances	Long-term debt and unamortized discount balances are as follows (in thousands): Face value of amended and restated loan $ 6,974 Fair value of all warrants (536 ) Accretion of debt discount 430 Balance at June 30, 2016 $ 6,868
Future Minimum Payments under Amended and Restated Loan and Security Agreement	Future minimum payments under the amended and restated loan and security agreement are as follows (in thousands): Year Ending December 31, 2016 $ 2,748 2017 4,579 Total future minimum payments 7,327 Unamortized interest (353 ) Debt discount (106 ) Total minimum payment 6,868 Current portion (5,067 ) Long-term debt $ 1,801

Stock Incentive Plans (Tables)

Stock Incentive Plans (Tables)	6 Months Ended
	Jun. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair Value of Employee Stock Options	The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. The fair value of employee stock options was estimated at the grant date using the following assumptions: Six Months Ended June 30, 2016 2015 Weighted-average grant date fair value $ 5.86 $ 11.56 Dividend yield — — Volatility 75 % 75 % Risk-free interest rate 1.45 % 1.65 % Expected life of options 6.1 years 6.1 years
Summary of Common Stock Reserved for Future Issuance	Common stock reserved for future issuance consists of the following at June 30, 2016: Common stock warrants outstanding under the underwriters agreement 182,600 Common stock warrants outstanding under the loan and security agreement 65,892 Common stock warrants outstanding under the Cambridge securities agreement 1,724,138 Common stock warrants outstanding under the private placement security agreements 5,290,936 Authorized for future grant or issuance under the amended and restated 2009 Stock Incentive Plan 2,919,703 Issuable under BDL and CARgenix acquisition agreements 619,834 Issuable under assignment agreement based upon achievement of certain milestones 80,000 10,883,103
2009 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Stock Option Activity	The following table summarizes stock option activity as of June 30, 2016 and the changes for the period then ended (dollar values in thousands): Options Outstanding Weighted- Average Exercise Price Aggregate Intrinsic Value Outstanding at December 31, 2015 2,957,616 $ 8.95 $ 4,506 Options Granted 462,950 $ 5.86 Options Canceled (443,481 ) $ 8.73 Options Exercised (89,976 ) $ 4.76 Outstanding at June 30, 2016 2,887,109 $ 8.62 $ 934

Nature of Operations and Busi31

Nature of Operations and Business Activities - Additional Information (Detail) - USD ($)	Jul. 11, 2016	Jul. 07, 2016	Jun. 08, 2016	May 02, 2016	Apr. 03, 2016	Oct. 31, 2014	Sep. 30, 2013	Jun. 30, 2016	Jun. 30, 2016	May 31, 2014	Jul. 31, 2013
Nature Of Operations And Business Activities [Line Items]
Warrant exercisable period						7 years	7 years
Maximum amount of equity and other securities authorized to offer								$ 250,000,000	$ 250,000,000		$ 100,000,000
Remaining amount of equity and other securities authorized to offer								50,000,000	50,000,000	$ 36,600,000
Common stock issued and sold under sales agreement									3,600,000
November 2014 Registration [Member]
Nature Of Operations And Business Activities [Line Items]
Remaining amount of equity and other securities authorized to offer								46,400,000	$ 46,400,000
Subsequent Event [Member]
Nature Of Operations And Business Activities [Line Items]
Treasury stock retired, shares		7,878,098
Yuhan Corporation [Member]
Nature Of Operations And Business Activities [Line Items]
Gross proceeds of common stock and warrants								$ 10,000,000
Foundation [Member]
Nature Of Operations And Business Activities [Line Items]
Common stock agreed to issue and sell									5,618,326
Purchase of common stock from foundation									7,878,098
Payments of common stock and warrants									$ 15,640,000
Cambridge Equities LP [Member]
Nature Of Operations And Business Activities [Line Items]
Warrants to purchase common stock									1,724,138
Common stock shares forfeited									500,000
Private Placement [Member] | Yuhan Corporation [Member]
Nature Of Operations And Business Activities [Line Items]
Warrant exercisable period				3 years
Warrant exercise price per share				$ 8.50
Common stock agreed to issue and sell				1,801,802
Warrants to purchase common stock				235,294
Gross proceeds of common stock and warrants				$ 10,000,000
Common stock price per share				$ 5.55
ABG Purchase Agreement [Member] | Private Placement [Member]
Nature Of Operations And Business Activities [Line Items]
Common stock issued under private placement					$ 50,000,000
Number of shares of common stock as is equal to the amount of such purchaser's investment divided by					$ 5.55
Threshold percentage of warrant to purchase shares sold and issued to purchaser					30.00%
Warrant exercisable period					3 years				3 years
Warrant exercise price per share					$ 8.50			$ 8.50	$ 8.50
Affiliate beneficial ownership percentage					9.99%
Warrants to purchase common stock								5,290,936
Gross proceeds of common stock and warrants								$ 150,000,000
Additional Purchase Agreements [Member] | Private Placement [Member] | Beijing Shijilongxin Investment Co Ltd [Member]
Nature Of Operations And Business Activities [Line Items]
Warrant exercisable period					3 years
Warrant exercise price per share					$ 8.50
Common stock agreed to issue and sell					8,108,108
Warrants to purchase common stock					1,176,471
Aggregate purchase price of common stock warrants					$ 45,000,000
Additional Purchase Agreements [Member] | Private Placement [Member] | FREJOY Investment Management Co Ltd [Member]
Nature Of Operations And Business Activities [Line Items]
Warrant exercisable period					3 years
Warrant exercise price per share					$ 8.50
Common stock agreed to issue and sell					8,108,108
Warrants to purchase common stock					1,176,471
Aggregate purchase price of common stock warrants					$ 45,000,000
Additional Purchase Agreements [Member] | Private Placement [Member] | Yuhan Corporation [Member]
Nature Of Operations And Business Activities [Line Items]
Warrant exercisable period					3 years
Warrant exercise price per share					$ 8.50
Common stock agreed to issue and sell					1,801,802
Warrants to purchase common stock					235,294
Aggregate purchase price of common stock warrants					$ 10,000,000
ABG [Member]
Nature Of Operations And Business Activities [Line Items]
Closed consideration of common stock and warrants			$ 150,000,000
Beijing Shijilongxin Investment Co Ltd and FREJOY Investment Management Co Ltd [Member]
Nature Of Operations And Business Activities [Line Items]
Common stock agreed to issue and sell			25,225,221
Warrants to purchase common stock			5,055,642
Gross proceeds of common stock and warrants			$ 140,000,000
Common stock price per share			$ 5.55
License and Collaboration Agreement [Member] | Les Laboratoires Servier [Member] | Subsequent Event [Member]
Nature Of Operations And Business Activities [Line Items]
Non-refundable up-front payment	$ 27,400,000

Significant Accounting Polici32

Significant Accounting Policies - Additional Information (Detail)	3 Months Ended			6 Months Ended
	Jun. 30, 2016USD ($)	Dec. 31, 2015USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)Segments	Jun. 30, 2015USD ($)
Significant Accounting Policies [Line Items]
Other-than-temporary impairment charges	$ 0			$ 0
Goodwill, Impairment	0	$ 0	$ 0	0	$ 0
Impairment losses of long-lived assets				$ 0
Number of operating segments | Segments				1
Minimum [Member]
Significant Accounting Policies [Line Items]
Estimated useful life of fixed asset				3 years
Maximum [Member]
Significant Accounting Policies [Line Items]
Estimated useful life of fixed asset				5 years
Grants Receivable [Member]
Significant Accounting Policies [Line Items]
Allowance for doubtful accounts	0	0		$ 0
Trade Accounts Receivable [Member]
Significant Accounting Policies [Line Items]
Allowance for doubtful accounts	$ 29,000	$ 4,000		$ 29,000

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Assets:
Total assets	$ 34,946	$ 97,366
Liabilities:
Total liabilities		5,520
Marketable securities [Member]
Assets:
Total assets	34,946	97,366
Quoted Prices in Active Markets (Level 1) [Member]
Assets:
Total assets	34,946	97,366
Liabilities:
Total liabilities		0
Quoted Prices in Active Markets (Level 1) [Member] | Marketable securities [Member]
Assets:
Total assets	34,946	97,366
Significant Other Observable Inputs (Level 2) [Member]
Assets:
Total assets	0	0
Liabilities:
Total liabilities		0
Significant Other Observable Inputs (Level 2) [Member] | Marketable securities [Member]
Assets:
Total assets	0	0
Significant Unobservable Inputs (Level 3) [Member]
Assets:
Total assets	0	0
Liabilities:
Total liabilities		5,520
Significant Unobservable Inputs (Level 3) [Member] | Marketable securities [Member]
Assets:
Total assets	$ 0	0
Derivative Liability [Member]
Liabilities:
Total liabilities		5,520
Derivative Liability [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Liabilities:
Total liabilities		0
Derivative Liability [Member] | Significant Other Observable Inputs (Level 2) [Member]
Liabilities:
Total liabilities		0
Derivative Liability [Member] | Significant Unobservable Inputs (Level 3) [Member]
Liabilities:
Total liabilities		$ 5,520

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Derivative Liability Measured at Fair Value Using Significant Unobservable Inputs (Level 3) (Detail) - Derivative Liability [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Beginning balance at December 31, 2015	$ 5,520
Gain on expiration of derivative liability	(5,520)
Ending balance at June 30, 2016	$ 0

Marketable Securities - Schedul

Marketable Securities - Schedule of Marketable Securities (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale securities, Fair Value	$ 34,946	$ 97,366
NantKwest common shares [Member]
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale securities, Cost	10,000
Available-for-sale securities, Gross Unrealized Gains	87,366
Available-for-securities, Gross Unrealized Losses	(62,420)
Available-for-sale securities, Fair Value	$ 34,946

Marketable Securities - Additio

Marketable Securities - Additional Information (Detail) - USD ($)	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Schedule Of Available For Sale Securities [Line Items]
Cost-method investments, aggregate carrying amount	$ 112,008,000	$ 112,008,000		$ 112,008,000
Unrealized loss		(62,420,000)	$ 0
NantKwest [Member]
Schedule Of Available For Sale Securities [Line Items]
Cost-method investments, aggregate carrying amount	10,000,000	10,000,000
Unrealized loss	$ 11,200,000	48,100,000
Unrealized gain (loss), tax		$ 0		$ 14,300,000

Notes Receivable - Additional I

Notes Receivable - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		6 Months Ended
	Jul. 31, 2016	Jun. 30, 2016	Jun. 30, 2016	Dec. 31, 2015
Accounts Notes And Loans Receivable [Line Items]
Stock subscription receivable		$ 43,502	$ 43,502	$ 0
Secured Promissory Notes [Member]
Accounts Notes And Loans Receivable [Line Items]
Consideration received, shares		9,640,060
Consideration received, value of shares		$ 53,500
Accrued interest rate per annum		5.00%
Promissory notes due date			2016-12
Secured Promissory Notes [Member] | Subsequent Event [Member]
Accounts Notes And Loans Receivable [Line Items]
Partial payment received with accrued interest	$ 10,000
Stock subscription receivable	$ 43,500

Investments - Additional Inform

Investments - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended			6 Months Ended
	Aug. 31, 2015	Jun. 30, 2016	Sep. 30, 2015	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Schedule Of Investments [Line Items]
Cost-method investments, aggregate carrying amount		$ 112,008,000			$ 112,008,000		$ 112,008,000
Cost method investments, impairment losses		$ 0		$ 0	$ 0	$ 0
TNK Therapeutics Inc [Member] | Membership Interest Purchase Agreement [Member] | CARgenix Holding LLC [Member]
Schedule Of Investments [Line Items]
Cash payment	$ 100,000
Minimum qualified financing	$ 50,000,000
Purchase agreement terms, description					In accordance with the March 2016, Amendment No. 1, in the event a Qualified Financing does not occur by September 15, 2016 or TNK does not complete an initial public offering of shares of its capital stock by October 15, 2016, in lieu of receiving shares of TNK pursuant to the acquisition, the Members shall receive an aggregate of 309,917 shares of Company common stock, subject to adjustment in certain circumstances.
Aggregate common stock to be issued, shares	309,917
Percentage of shares held in escrow	20.00%
Indemnification period					12 months
TNK Therapeutics Inc [Member] | Membership Interest Purchase Agreement [Member] | CARgenix Holding LLC [Member] | Acquired In-Process Research and Development Expense [Member]
Schedule Of Investments [Line Items]
Recognition of aggregate purchase price			$ 6,000,000
TNK Therapeutics Inc [Member] | Stock Purchase Agreement [Member] | B D L Products Inc [Member]
Schedule Of Investments [Line Items]
Cash payment	$ 100,000
Purchase agreement terms, description					In accordance with the March 2016, Amendment No. 1, in the event a Qualified Financing does not occur by September 15, 2016 or TNK does not complete an initial public offering of shares of its capital stock by September 30, 2016, in lieu of receiving shares of TNK pursuant to the acquisition, the Stockholders shall receive an aggregate of 309,917 shares of Company common stock, subject to adjustment in certain circumstances.
Aggregate common stock to be issued, shares	309,917
Percentage of shares held in escrow	20.00%
Indemnification period					12 months
TNK Therapeutics Inc [Member] | Stock Purchase Agreement [Member] | B D L Products Inc [Member] | Acquired In-Process Research and Development Expense [Member]
Schedule Of Investments [Line Items]
Recognition of aggregate purchase price			$ 6,000,000
TNK Therapeutics Inc [Member] | Class A [Member] | Membership Interest Purchase Agreement [Member] | CARgenix Holding LLC [Member]
Schedule Of Investments [Line Items]
Common stock to be issued, value	$ 6,000,000
TNK Therapeutics Inc [Member] | Class A [Member] | Stock Purchase Agreement [Member] | B D L Products Inc [Member]
Schedule Of Investments [Line Items]
Common stock to be issued, value	$ 6,000,000

Equity Method Investments - Add

Equity Method Investments - Additional Information (Detail)	Oct. 13, 2015USD ($)	Jun. 30, 2016USD ($)AntigenAntibody	Jun. 30, 2016USD ($)AntigenAntibody	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)AntigenAntibody	Jun. 30, 2015USD ($)	Jul. 31, 2015USD ($)	Apr. 30, 2015USD ($)
Schedule Of Equity Method Investments [Line Items]
Equity method investments		$ 59,090,000	$ 59,090,000		$ 58,119,000		$ 59,090,000
Net income (loss), Equity investments			470,000			$ 0	(29,000)	$ 0
Joint venture agreement second payment contribution	$ 20,000,000
Gain on derivative liability			0	$ 5,500,000		$ 0	$ 5,520,000	$ 0
Yuhan Corporation [Member] | Private Placement [Member]
Schedule Of Equity Method Investments [Line Items]
Gross proceeds of common stock and warrants			$ 10,000,000
NANTibody [Member]
Schedule Of Equity Method Investments [Line Items]
Initial joint funding										$ 100,000,000
Equity method investment ownership percentage										40.00%
Initial joint funding contributed										$ 40,000,000
Equity method investment ownership percentage		40.00%	40.00%				40.00%
Equity method investments		$ 39,900,000	$ 39,900,000				$ 39,900,000
Net income (loss), Equity investments			$ 322,000	806,000	(964,000)		$ (63,000)
Equity method investment, Current assets				100,400,000
Equity method investment, Current liabilities				628,000
NANTibody [Member] | Nant Cell [Member]
Schedule Of Equity Method Investments [Line Items]
Equity method investment ownership percentage										60.00%
Initial joint funding contributed										$ 60,000,000
Nant Cancer Stem LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Initial joint funding									$ 100,000,000
Equity method investment ownership percentage	20.00%								40.00%
Initial joint funding contributed									$ 40,000,000
Equity method investment ownership percentage		20.00%	20.00%				20.00%
Equity method investments		$ 18,200,000	$ 18,200,000				$ 18,200,000
Net income (loss), Equity investments			$ 148,000	739,000	$ (566,000)		$ 34,000
Equity method investment, Current assets				80,300,000
Equity method investment, Current liabilities				142,000
Nant Cancer Stem LLC [Member] | NantBioScience, Inc. [Member]
Schedule Of Equity Method Investments [Line Items]
Equity method investment ownership percentage									60.00%
Initial joint funding contributed									$ 60,000,000
Shanghai Three [Member]
Schedule Of Equity Method Investments [Line Items]
Equity method investment ownership percentage		25.00%	25.00%				25.00%
Equity method investments		$ 1,000,000	$ 1,000,000				$ 1,000,000
Equity method investment, Current assets				540,000
Equity method investment, Current liabilities				3,000,000
Equity Method Investment, Operating expenses				$ 0
Shenyang Sunshine Pharmaceutical Company Ltd [Member]
Schedule Of Equity Method Investments [Line Items]
Initial investment		$ 10,000,000	$ 10,000,000				$ 10,000,000
Number of chimeric antigen receptor | Antigen		2	2				2
Ownership percentage in joint venture		51.00%	51.00%				51.00%
Investments in joint venture		$ 0	$ 0				$ 0
Shenyang Sunshine Pharmaceutical Company Ltd [Member] | Private Placement [Member]
Schedule Of Equity Method Investments [Line Items]
Gross proceeds of common stock and warrants		$ 10,000,000
Shenyang Sunshine Pharmaceutical Company Ltd [Member] | TNK Therapeutics Inc [Member]
Schedule Of Equity Method Investments [Line Items]
Ownership percentage in joint venture		49.00%	49.00%				49.00%
Immune Oncia Therapeutics L L C
Schedule Of Equity Method Investments [Line Items]
Ownership percentage in joint venture		49.00%	49.00%				49.00%
Investments in joint venture		$ 0	$ 0				$ 0
Number of monoclonal antibodies | Antibody		2	2				2
Immune Oncia Therapeutics L L C | Yuhan Corporation [Member]
Schedule Of Equity Method Investments [Line Items]
Initial investment		$ 10,000,000	$ 10,000,000				$ 10,000,000
Ownership percentage in joint venture		51.00%	51.00%				51.00%

Goodwill and Intangible Asset40

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) [Line Items]
Goodwill	$ 20,626,000	$ 20,626,000		$ 20,626,000
Goodwill, Impairment	0	$ 0	$ 0	$ 0	$ 0
Patent rights [Member]
Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) [Line Items]
Estimated useful life of intangible asset				19 years
Amortization expense	1,250		1,250	$ 2,500	2,500
Acquired technology [Member]
Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) [Line Items]
Estimated useful life of intangible asset				19 years
Amortization expense	44,000		44,000	$ 88,000	88,000
Customer relationships [Member]
Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) [Line Items]
Estimated useful life of intangible asset				5 years
Amortization expense	$ 66,000		$ 66,000	$ 132,000	$ 132,000
Weighted average life [Member]
Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) [Line Items]
Identifiable intangible assets, weighted average life				15 years

Goodwill and Intangible Asset41

Goodwill and Intangible Assets - Summary of Company's Identifiable Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 4,820	$ 4,820
Accumulated Amortization	1,130	908
Intangibles, net	3,690	3,912
Customer relationships [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,320	1,320
Accumulated Amortization	668	536
Intangibles, net	652	784
Acquired technology [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	3,410	3,410
Accumulated Amortization	446	358
Intangibles, net	2,964	3,052
Patent rights [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	90	90
Accumulated Amortization	16	14
Intangibles, net	$ 74	$ 76

Goodwill and Intangible Asset42

Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense Related to Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
2016 (remaining 6 months)	$ 223
2,017	445
2,018	436
2,019	181
2,020	181
Thereafter	2,224
Intangibles, net	$ 3,690	$ 3,912

Significant Agreements and Co43

Significant Agreements and Contracts - Additional Information (Detail) shares in Millions	May 13, 2016USD ($)	Jun. 30, 2016USD ($)	Feb. 29, 2016USD ($)	Aug. 31, 2015USD ($)Antibody	Apr. 30, 2015USD ($)shares	Jul. 31, 2014USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Dec. 31, 2015USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Terminate notice of license										60 days
Warrant exercised date										2015-02
Cost-method investments, aggregate carrying amount		$ 112,008,000						$ 112,008,000		$ 112,008,000		$ 112,008,000
Grant revenue recognized as the related costs and expenses incurred								328,000	$ 459,000	$ 757,000	$ 697,000
Staph Grant III Award [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Period of grant										2 years
Amount of grant awards							$ 1,000,000
Grant revenue recognized as the related costs and expenses incurred								218,000	331,000	$ 457,000	417,000
Phase I STTR Grant [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Period of grant										2 years
Amount of grant awards						$ 300,000
Grant revenue recognized as the related costs and expenses incurred								98,000	38,000	$ 224,000	93,000
Myc Grant I Award [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Period of grant										1 year
Amount of grant awards										$ 225,000
Grant revenue recognized as the related costs and expenses incurred								0	56,000	$ 0	130,000
WISP1 Grant I Award [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Period of grant										1 year
Amount of grant awards										$ 225,000
Grant revenue recognized as the related costs and expenses incurred								0	21,000	$ 52,000	31,000
Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Aggregate purchase price of common stock warrants	$ 150,000,000
Nant Cell [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Vested equity received					$ 100,000,000
Common stock received | shares					10
Upfront payment period for recognition										10 years
Cost-method investments, aggregate carrying amount		100,000,000						100,000,000		$ 100,000,000
Nant Cell [Member] | Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalty rate percent of net sales					5.00%
Nant Cell [Member] | Upfront Payment [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue					$ 10,000,000
Mabtech Limited [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Aggregate purchase price of common stock warrants		20,000,000
Mabtech Limited [Member] | CHINA [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of monoclonal antibodies | Antibody				4
Additional payment for license agreement										30,000,000
Aggregate purchase price of common stock warrants		20,000,000
Licensing agreement, additional amounts payable		$ 150,000,000						150,000,000		150,000,000
General and administrative expenses [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Patent prosecution and maintenance costs								$ 2,000	$ 21,000	$ 22,000	$ 46,000
Acquired in-process research and development expense [Member] | Mabtech Limited [Member] | CHINA [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Initial payment for license agreement				$ 10,000,000
Additional payment for license agreement			$ 10,000,000

Loan and Security Agreement - A

Loan and Security Agreement - Additional Information (Detail)	1 Months Ended		6 Months Ended
	Oct. 31, 2014$ / sharesshares	Sep. 30, 2013USD ($)Bank$ / sharesshares	Jun. 30, 2016USD ($)	Mar. 31, 2014USD ($)Bank
Debt Instrument [Line Items]
Principal amount of loan agreement		$ 5,000,000
Number of banks provided term loan | Bank		2		2
Repayment of outstanding equipment loan balance		$ 762,000
Warrant received to purchase aggregate of common stock - shares | shares	34,642	31,250
Warrant received to purchase aggregate of common stock - exercise price | $ / shares	$ 12.99	$ 8
Warrant exercisable period	7 years	7 years
Debt discount			$ 536,000
Amended and restated principal amount of loan agreement		$ 5,000,000		$ 12,500,000
Interest rate	7.95%
Minimum percentage of pre-payment fees			1.00%
Maximum percentage of pre-payment fees			3.00%
Final fee			$ 781,000
Term Loan [Member]
Debt Instrument [Line Items]
Term loan maturity date	Sep. 30, 2017
Line of Credit [Member]
Debt Instrument [Line Items]
Debt discount		$ 215,000		$ 322,000

Loan and Security Agreement - S

Loan and Security Agreement - Schedule of Long-Term Debt and Unamortized Discount Balances (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Debt Disclosure [Abstract]
Face value of amended and restated loan	$ 6,974
Fair value of all warrants	(536)
Accretion of debt discount	430
Balance at June 30, 2016	$ 6,868

Loan and Security Agreement - F

Loan and Security Agreement - Future Minimum Payments under Amended and Restated Loan and Security Agreement (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Amount due in 2016	$ 2,748
Amount due in 2017	4,579
Total future minimum payments	7,327
Unamortized interest	(353)
Debt discount	(106)
Total minimum payment	6,868
Current portion	(5,067)	$ (4,835)
Long-term debt	$ 1,801	$ 4,394

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Apr. 03, 2016	Jul. 31, 2016	Jun. 30, 2016	Oct. 31, 2014	Sep. 30, 2013	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	May 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum amount of common stock authorized to offer			$ 50,000			$ 50,000		$ 50,000			$ 36,600
Commission on aggregate gross proceeds from sale of common stock								2.00%
Proceeds from issuance of common stock							$ 3,500	$ 95,751	$ 0
Common stock, shares issued			65,448,566			65,448,566		65,448,566		37,771,459
Warrant exercisable period				7 years	7 years
Stock subscription receivable			$ 43,502			$ 43,502		$ 43,502		$ 0
Secured Promissory Notes [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Consideration received, shares			9,640,060
Consideration received, value of shares			$ 53,500
Secured Promissory Notes [Member] | Subsequent Event [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Partial payment received with accrued interest		$ 10,000
Stock subscription receivable		43,500
ABG Purchase Agreement [Member] | Private Placement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average price of shares sold			$ 5.55			$ 5.55		$ 5.55
Common stock, shares issued			27,027,027			27,027,027		27,027,027
Warrants to purchase common stock						5,290,936
Gross proceeds of common stock and warrants						$ 150,000
Offering commissions and expenses						$ 4,200
Warrant exercisable period	3 years							3 years
Warrant exercise price per share	$ 8.50		$ 8.50			$ 8.50		$ 8.50
ABG Purchase Agreement [Member] | Private Placement [Member] | Secured Promissory Notes [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Consideration received, shares						9,640,060
Consideration received, value of shares						$ 53,500
ABG Purchase Agreement [Member] | Private Placement [Member] | Secured Promissory Notes [Member] | Subsequent Event [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Partial payment received with accrued interest		10,000
Stock subscription receivable		$ 43,500
Weighted average life [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average price of shares sold							$ 6.37

Stock Incentive Plans - Additio

Stock Incentive Plans - Additional Information (Detail) - USD ($)	1 Months Ended			3 Months Ended			6 Months Ended
	Oct. 31, 2015	May 31, 2015	May 31, 2014	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Sep. 30, 2009
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares authorized				750,000,000			750,000,000		750,000,000
Common stock reserved for issuance				10,883,103			10,883,103
Employee Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield							0.00%	0.00%
Expected life of options							6 years 1 month 6 days	6 years 1 month 6 days
2009 Non-Employee Director Grants [Member] | Non Employee Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance										8,000
Options vesting anniversary period							1 year
Shares available for grant				0			0
Option outstanding				0			0
2009 Non-Employee Director Grants [Member] | Non Employee Directors | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options exercisable period							10 years
2009 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options exercisable period							10 years
Option outstanding				2,887,109			2,887,109		2,957,616
Common stock, shares authorized				6,260,000			6,260,000
Employee option grants vested							25.00%
Unrecognized compensation cost related to unvested stock option grants				$ 6,206,000			$ 6,206,000
Period for recognized compensation cost							2 years 9 months 18 days
Options Granted, Options Outstanding							462,950
Options cancelled							443,481
2009 Stock Incentive Plan [Member] | Employee Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options vesting anniversary period							3 years
Stock options vesting rights under 2009 stock incentive plan							Employee option grants will generally vest 25% on the first anniversary of the original vesting commencement date, with the balance vesting monthly over the remaining three years.
2009 Stock Incentive Plan [Member] | Employee and Director [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation				1,082,000		$ 801,000	$ 2,120,000	$ 1,783,000
2009 Stock Incentive Plan [Member] | Non-Employee consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation				$ 44,000		571,000	$ 96,000	992,000
Subsidiary Equity Grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option outstanding				1,400,000			1,400,000
Stock options vesting rights under 2009 stock incentive plan							Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years.
Options Granted, Options Outstanding				0			0
Options cancelled				0			0
Stock options, contractual term	10 years
Subsidiary Equity Grants [Member] | Class A [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance	10,000,000
Subsidiary Equity Grants [Member] | TNK Therapeutics Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option outstanding				2,900,000			2,900,000
Stock options vesting rights under 2009 stock incentive plan							Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years.
Options Granted, Options Outstanding				0			402,000
Options, weighted average grant date fair value							$ 0.84
Options cancelled				100,000
Stock options, contractual term							10 years
Warrant shares exercisable		4,000,000
Warrant exercise price per share		$ 0.01
Warrants outstanding				9,500,000			9,500,000
Subsidiary Equity Grants [Member] | TNK Therapeutics Inc [Member] | Class A [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance		10,000,000
Subsidiary Equity Grants [Member] | LA Cell Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option outstanding				1,900,000			1,900,000
Stock options vesting rights under 2009 stock incentive plan							Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years.
Options Granted, Options Outstanding				0			401,500
Options, weighted average grant date fair value							$ 0.20
Options cancelled				201,500
Stock options, contractual term		10 years
Warrant shares exercisable		4,000,000
Warrant exercise price per share		$ 0.01
Warrants outstanding				9,500,000			9,500,000
Subsidiary Equity Grants [Member] | LA Cell Inc [Member] | Class A [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance		10,000,000
Subsidiary Equity Grants [Member] | Concortis Biosystems, Corp. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option outstanding				1,800,000			1,800,000
Stock options vesting rights under 2009 stock incentive plan							Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years.
Options Granted, Options Outstanding				0			9,750
Options, weighted average grant date fair value	$ 0.17
Options cancelled				0			420,000
Stock options, contractual term	10 years
Warrant shares exercisable	4,000,000
Warrant exercise price per share	$ 0.25
Warrants outstanding				9,500,000			9,500,000
Subsidiary Equity Grants [Member] | Concortis Biosystems, Corp. [Member] | Class A [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance	10,000,000
Subsidiary Equity Grants [Member] | Scintilla Pharmaceuticals, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option outstanding				1,000,000			1,000,000
Stock options vesting rights under 2009 stock incentive plan							Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years.
Options, weighted average grant date fair value					$ 0.01
Options cancelled				0			200,000
Stock options, contractual term	10 years
Warrant shares exercisable	4,000,000
Warrant exercise price per share	$ 0.01
Warrants outstanding				9,500,000			9,500,000
Subsidiary Equity Grants [Member] | Scintilla Pharmaceuticals, Inc [Member] | Class A [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance	10,000,000
Options Granted, Options Outstanding				0			2,000
Subsidiary Equity Grants [Member] | Sorrento Biologics Inc
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrant shares exercisable	4,000,000
Warrant exercise price per share	$ 0.01
Warrants outstanding				9,500,000			9,500,000
Subsidiary Equity Grants [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options vesting anniversary period	4 years
Subsidiary Equity Grants [Member] | Maximum [Member] | TNK Therapeutics Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options vesting anniversary period							4 years
Warrant exercisable period		4 years
Subsidiary Equity Grants [Member] | Maximum [Member] | LA Cell Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options vesting anniversary period		4 years
Warrant exercisable period		4 years
Subsidiary Equity Grants [Member] | Maximum [Member] | Concortis Biosystems, Corp. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options vesting anniversary period	4 years
Warrant exercisable period	4 years
Subsidiary Equity Grants [Member] | Maximum [Member] | Scintilla Pharmaceuticals, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options vesting anniversary period	4 years
Warrant exercisable period	4 years
Subsidiary Equity Grants [Member] | Maximum [Member] | Sorrento Biologics Inc
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrant exercisable period	4 years
Subsidiary Equity Grants [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options vesting anniversary period	2 years
Subsidiary Equity Grants [Member] | Minimum [Member] | TNK Therapeutics Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options vesting anniversary period							2 years
Warrant exercisable period		40 months
Subsidiary Equity Grants [Member] | Minimum [Member] | LA Cell Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options vesting anniversary period		2 years
Warrant exercisable period		40 months
Subsidiary Equity Grants [Member] | Minimum [Member] | Concortis Biosystems, Corp. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options vesting anniversary period	2 years
Warrant exercisable period	40 months
Subsidiary Equity Grants [Member] | Minimum [Member] | Scintilla Pharmaceuticals, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options vesting anniversary period	2 years
Warrant exercisable period	40 months
Subsidiary Equity Grants [Member] | Minimum [Member] | Sorrento Biologics Inc
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrant exercisable period	40 months
Subsidiary Equity Grants [Member] | Non-Employee consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation				$ 44,000		0	$ 92,000	0
Subsidiary Equity Grants [Member] | CEO [Member] | TNK Therapeutics Inc [Member] | Class B [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrant granted to purchase common stock		9,500,000
Voting rights							10 to 1
Subsidiary Equity Grants [Member] | CEO [Member] | LA Cell Inc [Member] | Class B [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrant granted to purchase common stock		9,500,000
Voting rights							10 to 1
Subsidiary Equity Grants [Member] | CEO [Member] | Concortis Biosystems, Corp. [Member] | Class B [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrant granted to purchase common stock	9,500,000
Voting rights							10 to 1
Subsidiary Equity Grants [Member] | CEO [Member] | Scintilla Pharmaceuticals, Inc [Member] | Class B [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrant granted to purchase common stock	9,500,000
Voting rights							10 to 1
Subsidiary Equity Grants [Member] | CEO [Member] | Sorrento Biologics Inc | Class B [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrant granted to purchase common stock	9,500,000
Voting rights							10 to 1
Subsidiary Equity Grants [Member] | Director [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation				41,000		0	$ 83,000	0
Period for recognized compensation cost							3 years 2 months 12 days
Unrecognized compensation cost related to unvested stock option and warrant grants				$ 451,000			$ 451,000
Subsidiary Equity Grants [Member] | Directors and Non-Employee Consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Method used to determine the fair value of stock option and warrant							Black-Scholes option and warrant pricing model
Dividend yield							0.00%
Risk-free interest rate, minimum							1.39%
Risk-free interest rate, maximum							1.74%
Expected volatility, minimum							75.00%
Expected volatility, maximum							77.00%
Subsidiary Equity Grants [Member] | Directors and Non-Employee Consultants [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life of options							6 years 1 month 6 days
Subsidiary Equity Grants [Member] | Directors and Non-Employee Consultants [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life of options							4 years
Subsidiary Equity Grants [Member] | Directors and Consultants [Member] | Ark Animal Health, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options vesting anniversary period			1 year
Option outstanding				351,000			351,000
Stock-based compensation				$ 0		$ 22,000	$ 0	$ 55,000
Unrecognized compensation cost related to unvested stock option grants				$ 0			$ 0
Options Granted, Options Outstanding			600,000
Stock options, contractual term			10 years

Stock Incentive Plans - Summary

Stock Incentive Plans - Summary of Stock Option Activity (Detail) - 2009 Stock Incentive Plan [Member] $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option Outstanding Beginning Balance | shares	2,957,616
Options Granted, Options Outstanding | shares	462,950
Options Canceled, Options Outstanding | shares	(443,481)
Options Exercised, Options Outstanding | shares	(89,976)
Option Outstanding Ending Balance | shares	2,887,109
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 8.95
Options Granted, Weighted Average Exercise Price | $ / shares	5.86
Options Canceled, Weighted Average Exercise Price | $ / shares	8.73
Options Exercised, Weighted Average Exercise Price | $ / shares	4.76
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 8.62
Aggregate Intrinsic Value, Beginning Balance | $	$ 934	$ 4,506

Stock Incentive Plans - Fair Va

Stock Incentive Plans - Fair Value of Employee Stock Options (Detail) - Employee Stock Option [Member] - $ / shares	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average grant date fair value	$ 5.86	$ 11.56
Dividend yield	0.00%	0.00%
Volatility	75.00%	75.00%
Risk-free interest rate	1.45%	1.65%
Expected life of options	6 years 1 month 6 days	6 years 1 month 6 days

Stock Incentive Plans - Summa51

Stock Incentive Plans - Summary of Common Stock Reserved for Future Issuance (Detail)	Jun. 30, 2016shares
Class Of Stock [Line Items]
Common stock reserved for future issuance	10,883,103
Underwriters Agreement [Member] | Warrant [Member]
Class Of Stock [Line Items]
Common stock reserved for future issuance	182,600
Loan and Security Agreement [Member] | Warrant [Member]
Class Of Stock [Line Items]
Common stock reserved for future issuance	65,892
Cambridge Securities Agreement [Member] | Warrant [Member]
Class Of Stock [Line Items]
Common stock reserved for future issuance	1,724,138
Private Placement Security Agreements [Member] | Warrant [Member]
Class Of Stock [Line Items]
Common stock reserved for future issuance	5,290,936
2009 Stock Incentive Plan [Member]
Class Of Stock [Line Items]
Common stock reserved for future issuance	2,919,703
BDL and CARgenix [Member]
Class Of Stock [Line Items]
Common stock reserved for future issuance	619,834
Assignment Agreement [Member]
Class Of Stock [Line Items]
Common stock reserved for future issuance	80,000

Investment in Variable Intere52

Investment in Variable Interest Entity - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	6 Months Ended
	Sep. 30, 2015	Jun. 30, 2016	Jun. 30, 2016	Jun. 30, 2015
Variable Interest Entity [Line Items]
Acquired in-process research and development			$ 30,000	$ 0
LA Cell Inc [Member]
Variable Interest Entity [Line Items]
Upfront payment	$ 2,000
Additional license payment			$ 5,000
Ownership of outstanding shares, voting rights percentage			48.00%
Acquired in-process research and development		$ 3,000	$ 5,000

Derivative Liability - Addition

Derivative Liability - Additional Information (Detail) - USD ($)	Oct. 13, 2015	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Derivative [Line Items]
Common stock, par value		$ 0.0001			$ 0.0001		$ 0.0001
Gain on derivative liability		$ 0	$ 5,500,000	$ 0	$ 5,520,000	$ 0
Derivative liability		$ 0			$ 0		$ 5,520,000
NantKwest [Member]
Derivative [Line Items]
Number of common shares held		5,600,000			5,600,000
Common stock, par value		$ 0.0001			$ 0.0001
Call Option [Member]
Derivative [Line Items]
Contractual option premium associated with option agreement			$ 0		$ 0
Call Option [Member] | Cambridge Equities LP [Member]
Derivative [Line Items]
Underlying maximum shares	2,000,000
Number of shares right to purchase			2,000,000
Strike price per share			$ 15.295

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Unrecognized tax benefits	$ 1,800,000	$ 0	$ 1,800,000	$ 0
Related interest and penalty	0	$ 0	0	$ 0
Significant change in uncertain tax positions in the next 12 months	$ 0		$ 0

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	May 13, 2016USD ($)Transaction	Jun. 30, 2016USD ($)ft²
Other Commitments [Line Items]
Potential loss on matter or to estimate		$ 0
Number of transactions to purchase common stock and warrants | Transaction	4
Potential loss on derivative action or to estimate		0
Security deposit		$ 346,000
Corporate office and laboratory space [Member] | San Diego, California [Member]
Other Commitments [Line Items]
Leased office space | ft²		43,000
Non-cancelable operating lease amended, expiration date		Dec. 31, 2025
Laboratory and office space [Member] | San Diego, California [Member]
Other Commitments [Line Items]
Leased office space | ft²		10,875
Non-cancelable operating lease amended, expiration date		Apr. 30, 2017
Laboratory and office space two [Member] | San Diego, California [Member]
Other Commitments [Line Items]
Leased office space | ft²		6,350
Non-cancelable operating lease amended, expiration date		Jun. 30, 2018
Maximum [Member]
Other Commitments [Line Items]
Aggregate purchase price of common stock warrants	$ 150,000,000

Related Party Agreements - Addi

Related Party Agreements - Additional Information (Detail) - USD ($)

Oct. 13, 2015

Jun. 30, 2016

Jul. 31, 2015

May 31, 2015

Dec. 31, 2014

Jun. 30, 2016

Mar. 31, 2016

Jun. 30, 2015

Jun. 30, 2016

Jun. 30, 2015

Dec. 31, 2015

Apr. 30, 2015

Related Party Transaction [Line Items]

Investments in common stock

$ 112,008,000

$ 112,008,000

$ 112,008,000

$ 112,008,000

Gain on derivative liability

0

$ 5,500,000

$ 0

5,520,000

$ 0

Derivative liability

0

0

0

$ 5,520,000

NantBioScience, Inc. [Member]

Related Party Transaction [Line Items]

Number of common stock shares acquired

1,000,000

Investments in common stock

$ 10,000,000

Call Option [Member]

Related Party Transaction [Line Items]

Option premium associated with option agreement

$ 0

0

Levena Biopharma Co. LTD (Levena) [Member]

Related Party Transaction [Line Items]

Related party, products purchases

0

$ 117,000

350,000

$ 415,000

Investor [Member] | Securities Purchase Agreement [Member]

Related Party Transaction [Line Items]

Common stock shares to be issued in the future

7,200,000

Share price

$ 5.80

Common stock shares subscribed, subscription receivable

$ 41,700,000

Number of common stock shares called by warrants

1,700,000

Warrant exercisable period

3 years

Warrant exercise price per share

$ 5.80

NantKwest [Member] | Development And License Agreement [Member]

Related Party Transaction [Line Items]

Number of common stock shares acquired

5,600,000

Investments in common stock

$ 10,000,000

Nant Cell [Member]

Related Party Transaction [Line Items]

Payments to acquire interest in joint venture

$ 40,000,000

Non-refundable up-front payment

10,000,000

Vested equity received

$ 100,000,000

Cambridge Equities LP [Member] | Call Option [Member]

Related Party Transaction [Line Items]

Underlying maximum shares

2,000,000

Number of shares right to purchase

2,000,000

Strike price per share

$ 15.295

NantPharma [Member] | Stock Sale And Purchase Agreement [Member]

Related Party Transaction [Line Items]

Upfront payments received

$ 90,050,000

Regulatory and sales milestones payment receivable

$ 1,200,000,000

Mabtech Limited [Member]

Related Party Transaction [Line Items]

Payable for license agreement

30,000,000

30,000,000

30,000,000

Aggregate purchase price of common stock warrants

$ 20,000,000

Yuhan Corporation [Member]

Related Party Transaction [Line Items]

Gross proceeds of common stock and warrants

$ 10,000,000

3SBio [Member]

Related Party Transaction [Line Items]

Gross proceeds of common stock and warrants

$ 10,000,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)	Aug. 02, 2016	Jul. 11, 2016	Jul. 07, 2016	Jun. 30, 2016
Subsequent Event [Member]
Subsequent Event [Line Items]
Treasury stock retired, shares			7,878,098
Foundation [Member]
Subsequent Event [Line Items]
Common stock agreed to issue and sell				5,618,326
Common stock shares repurchased				7,878,098
Payments of common stock and warrants				$ 15,640,000
Cambridge Equities LP [Member]
Subsequent Event [Line Items]
Common stock shares forfeited				500,000
Warrants to purchase common stock				1,724,138
Les Laboratoires Servier [Member] | Subsequent Event [Member] | License and Collaboration Agreement [Member]
Subsequent Event [Line Items]
Non-refundable up-front payment		$ 27,400,000
Scintilla Pharmaceuticals, Inc [Member] | Minimum [Member]
Subsequent Event [Line Items]
Indemnification period				6 months
Scintilla Pharmaceuticals, Inc [Member] | Maximum [Member]
Subsequent Event [Line Items]
Indemnification period				12 months
Scintilla Pharmaceuticals, Inc [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Cash consideration to equity holders	$ 100
Business combination, purchase agreement, contractual term	2 years
Issued shares of common stock value	$ 70,000,000
Percentage of shares held in escrow	20.00%